[6] Defossez G, Le Guyader-Peyro S, Uhry Z, Grosclau P, Colonna M, Dantony E, et al. National estimates of cancer incidence and mortality in metropolitan France between 1990 and 2018 n.d.

[7] Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol 2022;82:529–42, doi: http://dx.doi.org/10.1016/j.eurouro.2022.08.019.

[8] Znaor A, Lortet-Tieulent J, Laversne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 2015;67:519–30, doi: http://dx.doi.org/10.1016/j.eurouro.2014.10.002.

[9] Seloğ C, Li P, Chanudet E, Muller DC. Variability of sex disparities in cancer incidence over 30 years: the striking case of kidney cancer. Eur Urol Focus 2018;4:586–90, doi: http://dx.doi.org/10.1016/j.euf.2017.01.006.

[10] Haas NB, Nathanson KL. Hereditary renal cancer syndromes. Adv Chronic Kidney Dis 2014;21:81–90, doi: http://dx.doi.org/10.1053/j.ackd.2013.10.001 [10.1053/j.ackd.2013.10.001].

[11] Du W, Guo K, Jin H, Sun L, Ruan S, Song Q. Association between metabolic syndrome and risk of renal cell cancer: a meta-analysis. Front Oncol 2022;12:928619, doi: http://dx.doi.org/10.3389/fonc.2022.928619.

[12] Graff RE, Wilson KM, Sanchez A, Chang SL, McDermott DF, Choueiri TK, et al. Obesity in relation to renal cell carcinoma incidence and survival in three prospective studies. Eur Urol 2022;82:247–51, doi: http://dx.doi.org/10.1016/j.eurouro.2022.04.032.

[13] Deng Z, Hajihoseini M, Moore JX, Khan S, Graff RE, Bondy ML, et al. Lifetime body weight trajectories and risk of renal cell cancer: a large U.S. prospective cohort study. Cancer Epidemiol Biomarkers Prev 2023;32:1651–9, doi: http://dx.doi.org/10.1158/1055-9965.EPI-23-0668.

[14] Al-Bayati O, Hasan A, Pruthi D, Kaushik D, Liss MA. Systematic review of modifiable risk factors for kidney cancer. Eur Urol Urol 2019;37:359–71, doi: http://dx.doi.org/10.1016/j.urolonc.2018.12.008.

[15] Alcala M, Mariosa D, Smith-Byrke K, Nasrollahzadeh Nesheli D, Carreras-Torres R, Ardanaz Aicua E, et al. The relationship between blood pressure and risk of renal cell carcinoma. Int J Epidemiol 2022;51:1317–27, doi: http://dx.doi.org/10.1093/ije/dyc042.

[16] Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol 2013;190:1657–61, doi: http://dx.doi.org/10.1016/j.juro.2013.04.130.

[17] Liu X, Peveri G, Bosetti C, Bagnardi V, Specchia D, Gallus S, et al. Dose-response relationships between cigarette smoking and kidney cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2019;142:86–93, doi: http://dx.doi.org/10.1016/j.critrevonc.2019.07.019.

[18] Christensson A, Savage C, Sjoberg DD, Cronin AM, Frank O'Brien M, Lowrance W, et al. Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. Int J Cancer 2013;133:1452–8, doi: http://dx.doi.org/10.1002/ijc.28144.

[19] Pan H-C, Sun C-Y, Wu I-W, Tsai T-L, Sun C-C, Lee C-C. Higher risk of malignant neoplasms in young adults with end-stage renal disease receiving haemodialysis: a nationwide population-based study. Nephrology (Carlton) 2019;24:1165–71, doi: http://dx.doi.org/10.1111/ nep.13555.

[20] Lowrance WT, Ordóñez J, Udaltsova N, Russo P, Go AS. CKD and the risk of incident cancer. J Am Nephrol Nephrol 2014;25:2327, doi: http://dx.doi.org/10.1681/ASN.2013060604.

[21] Åkerlund J, Holmberg E, Lindblad P, Stendahl M, Ljungberg B, Thorstenson A, et al. Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study. Scand J Urol 2021;55:209–14, doi: http://dx.doi.org/10.1080/21681805.2021.1900387.

[22] Decree No. 2021-636 of 20 May 2021 revising and supplementing the tables of occupational diseases appended to Book IV of the Social Security Code. 2021.

[23] Suttinun O, Luepromchai E, Müller R. Metabolism of trichloroethylene: concepts, limitations and available strategies for sustained biodegradation. Rev Environ Sci Biotechnol 2013;12:99–114, doi: http://dx.doi.org/10.1007/s11157-012-9291-x.

[24] Order of 4 May 1984 prohibiting the sale of trichlorethylene to minors and prohibiting preparations containing more than 5%. 1984.

[25] Commission Regulation (EU) No 348/2013 of 17 April 2013 amending Annex XIV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Text with EEA relevance 2013108.

[26] Moore SK, Lee I-M, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med 2016;176:816–25, doi: http://dx.doi.org/10.1001/jaminternmed.2016.1548.

[27] Jia L, Jia Q, Shang Y, Dong X, Li L. Vitamin C intake and risk of renal cell carcinoma: a meta-analysis. Sci Rep 2015;5:17921, doi: http://dx.doi.org/10.1038/srep17921.

[28] Tahbaz R, Schmid M, Merseburger AS. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol 2018;28:62–79, doi: http://dx.doi.org/10.1097/MOU.0000000000000454.

[29] Zhang S, Jia Z, Yan Z, Yang J. Consumption of fruits and vegetables and risk of renal cell carcinoma: a meta-analysis of observational studies. Oncotarget 2017;8:27892–903, doi: http://dx.doi.org/10.18632/oncotarget.15841.

[30] Liao Z, Fang Z, Gou S, Luo Y, Liu Y, He Z, et al. The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies. BMC Med 2022;20:39, doi: http://dx.doi.org/10.1186/s12916-021-02229-5.

[31] Campi R, Rebez G, Klatte T, Roussel E, Ouizad I, Ingels A, et al. Effect of smoking, hypertension and lifestyle factors on kidney cancer – perspectives for prevention and screening programmes. Nat Rev Urol 2023;20:669–81, doi: http://dx.doi.org/10.1038/s41585-023-00781-8.

[32] Diana P, Klatte T, Amparore D, Bertolo R, Carbonara U, Erdem S, et al. Screening programs for renal cell carcinoma: a systematic review by the EAU young academic

urologists renal cancer working group. World J Urol 2023;41:929–40, doi: http://dx.doi.org/10.1007/s00345-022-03939-6.

[33] Campi R, Stewart GD, Staehler M, Dabestani S, Kuczyk MA, Shuch BM, et al. Novel liquid biomarkers and innovative imaging for kidney cancer diagnosis: what can be implemented in our practice today? A systematic review of the literature. Eur Urol Oncol 2021;4:22–41, doi: http://dx.doi.org/10.1016/j.euro.2020.12.011.

[34] Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol 2018;36:1341–53, doi: http://dx.doi.org/10.1007/s00345-018-2286-7.

[35] Usher-Smith JA, Godoy A, Burge SW, Burbidge S, Cartledge J, Crosbie PAJ, et al. The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. BMJ Open 2022;12:e063018, doi: http://dx.doi.org/10.1136/bmjopen-2022-063018.

[36] Harrison H, Wood A, Pennells L, Rossi SH, Callister M, Cartledge J, et al. Estimating the effectiveness of kidney cancer screening within lung cancer screening programmes: a validation in UK biobank. Eur Urol Oncol 2023;6:351–3, doi: http://dx.doi.org/10.1016/j.euo.2023.02.012.

[37] Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer 2023;129:2927–40, doi: http://dx.doi.org/10.1002/cncr.34896.

[38] Forde C, Lim DHK, Alwan Y, Burghel G, Butland L, Cleaver R, et al. Hereditary leiomyomatosis and renal cell cancer: clinical, molecular, and screening features in a cohort of 185 affected individuals. Eur Urol Oncol 2020;3:764–72, doi: http://dx.doi.org/10.1016/j.euo.2019.11.002.

[39] Åkerlund J, Holmberg E, Lindblad P, Stendahl M, Ljungberg B, Thorstenson A, et al. Increased risk for renal cell carcinoma in end stage renal disease – a population-based case-control study. Scand J Urol 2021;55:209–14, doi: http://dx.doi.org/10.1080/21681805.2021.1900387.

[40] Goujon A, Verhoest G, Sallusto F, Branchereau J, Boutin J-M, Bessede T, et al. [Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant: the French guidelines from CTAFU]. Prog Urol 2021;31:18–23, doi: http://dx.doi.org/10.1016/j.purol.2020.04.030.

[41] Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998;51:203–5, doi: http://dx.doi.org/10.1016/s0090-4295 (97)00506-2.

[42] Sidhu PS, Cantisani V, Dietrich CF, Gilja OH, Saftoiu A, Bartels E, et al. The EFSUMB guidelines and recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound (CEUS) in non-hepatic applications: update 2017 (short version). Ultraschall Med 2018;39:154–80, doi: http://dx.doi.org/10.1055/s-0044-101254.

[43] Lan D, Qu H-C, Li N, Zhu X-W, Liu Y-L, Liu C-L. The value of contrast-enhanced ultrasonography and contrast-enhanced CT in the diagnosis of malignant renal cystic lesions: a meta-analysis. PLoS One 2016;11:e0155857, doi: http://dx.doi.org/10.1371/journal.pone.0155857.

[44] Rübenhalter J, Negrão de Figueiredo G, Mueller-Peltzer K, Clevert DA. Evaluation of renal lesions using contrast-enhanced ultrasound (CEUS): a 10-year retrospective European single-centre analysis. Eur Radiol 2018;28:4542–9, doi: http://dx.doi.org/10.1007/s00330-018-5504-1.

[45] Thomsen HS, Bush WH. Adverse effects of contrast medium: incidence, prevention and management. Drug Saf 1998;19:313–24, doi: http://dx.doi.org/10.2165/00002018-199819040-00006.

[46] van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin M-F, Bertolotto M, et al. Post-contrast acute kidney injury – part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018;28:2845–55, doi: http://dx.doi.org/10.1007/s00330-017-5246-5.

[47] van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin M-F, Bertolotto M, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018;28:2856–69, doi: http://dx.doi.org/10.1007/s00330-017-5247-4.

[48] Stacul F, Bertolotto M, Thomsen HS, Pozzato G, Ugolini D, Bellin M-F, et al. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2018;28:683–91, doi: http://dx.doi.org/10.1007/s00330-017-5023-5.

[49] Kim JI, Cho JY, Moon KC, Lee HJ, Kim SH. Segmental enhancement inversion at biphasic multidetector CT: characteristic finding of small renal oncocytoma. Radiology 2009;252:441–8, doi: http://dx.doi.org/10.1148/radiol.2522081180.

[50] Guzzo TJ, Pierorazio PM, Schaeffer EM, Fishman EK, Allaf ME. The accuracy of multidetector computerized tomography for evaluating tumor thrombus in patients with renal cell carcinoma. J Urol 2009;181:486–90, doi: http://dx.doi.org/10.1016/j.juro.2008.10.040 [discussion 491].

[51] Bosniak MA. The Bosniak renal cyst classification: 25 years later. Radiology 2012;262:781–5, doi: http://dx.doi.org/10.1148/radiol.11111595.

[52] Mileto E, Nelson RC, Paulson EK, Marin D. Dual-energy MDCT for imaging the renal mass. AJR Am J Roentgenol 2015;204:W640–7, doi: http://dx.doi.org/10.2214/AJR.14.14094.

[53] Çamlıdağ İ, Nural MS, Danacı M, Özden E. Usefulness of rapid KV-switching dual energy CT in renal tumor characterization. Abdom Radiol (NY) 2019;44:1841–9, doi: http://dx.doi.org/10.1007/s00261-019-01897-5.

[54] Sadoughi N, Krishna S, Macdonald DB, Chatelain R, Flood TA, McInnes MDF, et al. Diagnostic accuracy of attenuation difference and iodine concentration thresholds at rapid-kilovoltage-switching dual-energy CT for detection of enhancement in renal
masses. AJR Am J Roentgenol 2019;213:619-25, doi:http://dx.doi.org/10.2214/AJR.18.20990.

[55] Dai C, Cao Y, Jia Y, Ding Y, Sheng R, Zeng M, et al. Differentiation of renal cell carcinoma subtypes with different iodine quantification methods using single-phase contrast-enhanced dual-energy CT: areal vs. volumetric analyses. Abdom Radiol (NY) 2018;43:672-8, doi:http://dx.doi.org/10.1007/s00261-017-1253-x.

[56] Stehlé T, Wei F, Brabant S, Luciani A, Grimbert J, Prié D, et al. Glomerular filtration rate measured based on iomeprol clearance assessed at CT urography in living kidney donor candidates. Radiology 2023;303:e230567, doi:http://dx.doi.org/10.1148/radiol.230567.

[57] Reizine E, Blain M, Pescatori L, Longère B, Ingels A, Boughamni W, et al. Applicability of Bosniak 2019 for renal mass classification on portal venous phase at the era of spectral CT imaging using rapid kV-switching dual-energy CT. Eur Radiol 2024;34:1816-24, doi:http://dx.doi.org/10.1007/s00330-023-10145-w.

[58] Zhang H, Li F, Jing M, Xi H, Zheng Y, Liu J. Nomogram combining pre-operative clinical characteristics and spectral CT parameters for predicting the WHO/ISUP pathological grading in clear cell renal cell carcinoma. Abdom Radiol (NY) 2024;49:1185-93, doi:http://dx.doi.org/10.1007/s00261-024-04199-7.

[59] Liang X, Xue C, Huang X, Wei J, Zhou J. Value of energy spectrum CT parameters in the differential diagnosis of high-grade clear cell renal cell carcinoma and type II papillary renal cell carcinoma. Acta Radiol 2022;63:545-52, doi:http://dx.doi.org/10.1177/0284115211002830.

[60] Schieda N, Kieler AZ, Al Dandan O, McInnes MDF, Flood TA. Ten uncommon and unusual variants of renal angiomyolipoma (AML): radiologic-pathologic correlation. Clin Radiol 2015;70:206-20, doi:http://dx.doi.org/10.1016/j.crad.2014.10.001.

[61] Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009;182:844-53, doi:http://dx.doi.org/10.1016/j.juro.2009.05.035.

[62] Wagner B, Drel V, Gorin Y. Pathophysiology of gadoxinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1–F11, doi:http://dx.doi.org/10.1152/ajprenal.00166.2016.

[63] Schieda N, van der Pol CB, Moosavi B, McInnes MDF, Mai KT, Flood TA. Intracellular lipid in papillary renal cell carcinoma (pRCC): T2 weighted (T2W) MRI and pathologic correlation. Eur Radiol 2015;25:2134-42, doi:http://dx.doi.org/10.1007/s00330-015-3610-x.

[64] Cornelis F, Grenier N. Multiparametric magnetic resonance imaging of solid renal tumors: a practical algorithm. Semin Ultrasound CT MR 2017;38:47–58, doi:http://dx.doi.org/10.1053/j.sult.2016.08.009.

[65] de Leon AD, Kapur P, Pedrosa I. Radiomics in kidney cancer: Magn Reson Imaging Clin N Am 2019;27:1–13, doi:http://dx.doi.org/10.1016/j.mrc2018.08.005.

[66] Lopes Vendrami C, Parada Villavicencio C, DeJulio TJ, Chatterjee A, Casalino DD, Horowitz JM, et al. Differentiation of solid renal tumors with multiparametric MR imaging. Radiographics 2017;37:2026-42, doi:http://dx.doi.org/10.1148/rg.2017170039.

[67] Karlo CA, Donati OF, Burger IA, Zheng J, Moskowitz CS, Hricak H, et al. MR imaging of renal cortical tumours: qualitative and quantitative chemical shift imaging parameters. Eur Radiol 2013;23:1738-44, doi:http://dx.doi.org/10.1007/s00330-012-2758-x.

[68] Galmiche C, Bernhard J-C, Yacoub M, Ravaud A, Grenier N, Cornelis F. Is multiparametric MRI useful for differentiating oncocytomas from chromophobe renal cell carcinomas? AJR Am J Roentgenol 2017;208:343–50, doi:http://dx.doi.org/10.2214/AJR.16.16832.

[69] Ludwig DR, Ballard DH, Shetty AS, Siegel CL, Yano M. Apparent diffusion coefficient distinguishes malignancy in T1-hyperintense small renal masses. AJR Am J Roentgenol 2020;214:114–21, doi:http://dx.doi.org/10.2214/AJR.19.21907.

[70] Maurer MH, Härmä KH, Thoeny H. Diffusion-weighted genitourinary imaging. Urol Clin North Am 2018;45:407-25, doi:http://dx.doi.org/10.1016/j.ucl.2018.03.003.

[71] Schieda N, Krishna S, McInnes MDF, Moosavi B, Alrashed A, Moreland R, et al. Utility of MRI to differentiate clear cell renal cell carcinoma adrenal metastases from adrenal adenomas. AJR Am J Roentgenol 2017;209:W152-9, doi:http://dx.doi.org/10.2214/AJR.16.17649.

[72] Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32:69-118.

[73] Mueller-Lisse UG, Mueller-Lisse UL. Imaging of advanced renal cell carcinoma. World J Urol 2018;28:253-61, doi:http://dx.doi.org/10.1007/s00345-010-0557-z.

[74] Kabala JE, Gillatt DA, Persad RA, Peny JB, Gingell JC, Chadwick D. Magnetic resonance imaging in the staging of renal cell carcinoma. Br J Radiol 1991;64:683-9, doi:http://dx.doi.org/10.1259/0007-1285-64-764-683.

[75] Hallscheidt PJ, Fink C, Haferkamp A, Bock M, Luburic A, Zuna I, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr 2005;29:64-8, doi:http://dx.doi.org/10.1097/01.rct.0000146113.56194.6d.

[76] Yano M, Fowler KJ, Srisuwan S, Salter A, Siegel CL. Quantitative multiparametric MR analysis of small renal lesions: correlation with surgical pathology. Abdom Radiol (NY) 2018;43:3390-9, doi:http://dx.doi.org/10.1007/s00261-018-1612-2.

[77] Basile G, Fallara G, Verri P, Uleri A, Chiti A, Gianolli L, et al. The role of 99mTc-sestamibi single-photon emission computed tomography/computed tomography in the diagnostic pathway for renal masses: a systematic review and meta-analysis. Eur Urol 2024;85:63-71, doi:http://dx.doi.org/10.1016/j.eurouro.2023.07.013.

[78] Schober JP, Braun A, Ginsburg KB, Bell S, Castro Bigalli AA, Chen M, et al. Clinical performance of technetium-99m-sestamibi SPECT/CT imaging in differentiating oncocytic tumors from renal cell carcinoma in routine clinical practice. J Urol 2023;210:438-45, doi:http://dx.doi.org/10.1097/JU.0000000000003557.

[79] Lindenberg L, Mena E, Choyke PL, Bouchelouche K. PET imaging in renal cancer. Curr Opin Oncol 2019;31:216-21, doi:http://dx.doi.org/10.1097/CCO.0000000000000518.

[80] Hekman MCH, Rijpkema M, Aarntzen EH, Mulder CF, Langenhuijsen JF, Oosterwijk E, et al. Positron emission tomography/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol 2018;74:257-60, doi:http://dx.doi.org/10.1016/j.eurouro.2018.04.026.

[81] Minn I, Koo SMM, Lee HS, Brummet M, Rowe SP, Gorin MA, et al. [64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget 2016;7:56471-9, doi:http://dx.doi.org/10.18632/oncotarget.10602.

[82] Shuch BB, Pantuck AJ, Bernhard JC, Morris MA, Master JT, Scott AM, et al. Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON). J Clin Oncol 2023 [LBA602].

[83] Mühlbauer J, Egen L, Kowalewski K-F, Grilli M, Walach MT, Westhoff N, et al. Radiomics in renal cell carcinoma – a systematic review and meta-analysi. Cancers (Basel) 2021;13:1348, doi:http://dx.doi.org/10.3390/cancers13061348.

[84] Rallis KS, Kleeman SO, Grant M, Ordidge KL, Sahdev A, Powles T. Radiomics for renal cell carcinoma: predicting outcomes from immunotherapy and targeted therapies – a narrative review. Eur Urol Focus 2021;7:717–21, doi:http://dx.doi.org/10.1016/j.euf.2021.04.024.

[85] Rosevear HM, Gellhaus PT, Lightfoot AJ, Kresowik TP, Joudi FN, Tracy CR. Utility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk: renal nephrometry scoring system. BJO Int 2012;109:700-5, doi:http://dx.doi.org/10.1111/j.1464-410X.2011.10452.x.

[86] Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol 2009;56:786-93, doi:http://dx.doi.org/10.1016/j.eurouro.2009.07.040.

[87] Vecchia A, Antonelli A, Uzzo RG, Novara G, Kutikov A, Ficarra V, et al. Predictive value of nephrometry scores in nephron-sparing surgery: a systematic review and meta-analysis. Eur Urol Focus 2020;6:490-504, doi:http://dx.doi.org/10.1016/j.euf.2019.11.004.

[88] Heng DYC, Xie W, Regan MM, Warren MA, Golshan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9, doi:http://dx.doi.org/10.1200/JCO.2008.21.4809.

[89] Heng DYC, Xie W, Regan MM, Warren MA, Golshan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9, doi:http://dx.doi.org/10.1200/JCO.2008.21.4809.

[90] Sufrin G, Chasan S, Golia A, Murphy GP. Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 1989;7:158-71.

[91] Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 2015;313:837-46, doi:http://dx.doi.org/10.1001/jama.2015.0602.

[92] Huang WC, Levey AS, Serio AM, Snyder J, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-40, doi:http://dx.doi.org/10.1016/S1470-2045(06)07080-3.

[93] Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs – part A: renal, penile, and testicular tumours. Eur Urol 2022;82:458-68, doi:http://dx.doi.org/10.1016/j.eurouro.2022.06.016.

[94] Li T, Chen J, Jiang Y, Ning X, Peng S, Wang J, et al. Multilocular cystic renal cell neoplasm of low malignant potential: a series of 76 cases. Clin Genitourin Cancer 2016;14:e553-7, doi:http://dx.doi.org/10.1016/j.cgc.2016.03.017.

[95] Tretiakova M, Mehta V, Kocherginsky M, Minor A, Shen SS, Sirintrapun SJ, et al. Predominantly cystic clear cell renal cell carcinoma and multicellular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch 2018;473:85-93, doi:http://dx.doi.org/10.1007/s00428-018-2371-8.

[96] Cancer Genome Atlas Research Network. Linehan WM, Vickers PT, Ricketts CJ, Creighton CJ, Fei SS, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374:135-45, doi:http://dx.doi.org/10.1056/NEJMoa1505917.

[97] Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T. Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 2020;44:943-54, doi:http://dx.doi.org/10.1097/PAS.00000000000001457.

[98] Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, et al. Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol 2021;34:1167-84, doi:http://dx.doi.org/10.1038/s41379-021-00737-6.

[99] Trpkov K, Abou-Ouf H, Hes O, Lopez JI, Nesi G, Comperat E, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a distinct entity. Am J Surg Pathol 2017;41:1299-308, doi:http://dx.doi.org/10.1097/PAS.0000000000000838.

[100] Argani P, Reuter VE, Zhang L, Sung Y-S, Ning Y, Epstein JI, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 2016;40:1484-95, doi:http://dx.doi.org/10.1097/PAS.0000000000000720.

[101] Argani P, Antonescu CR, Couturier J, Fournet J-C, Sciot R, Debiec-Rychter M, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural,
and molecular analysis of an entity associated with the (X;1)(p11.2;q21). Am J Surg Pathol 2002;26:1553-66, doi:http://dx.doi.org/10.1097/00000478-200212000-00003.

[102] Xia Q-Y, Wang X-T, Fang R, Wang Z, Zhao M, Chen H, et al. Clinicopathologic and molecular analysis of the TFEB fusion variant reveals new members of TFEB translocation renal cell carcinomas (RCCs): expanding the genomic spectrum. Am J Surg Pathol 2020;44:477-89, doi:http://dx.doi.org/10.1097/PAS.00000000000001408.

[103] Kuroda N, Trpkov K, Gao Y, Tretiakova M, Liu YJ, Ulamec M, et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol 2020;33:2564-79, doi:http://dx.doi.org/10.1038/s41379-020-0578-0.

[104] Jia L, Carlo MI, Khan H, Nanjangud GJ, Rana S, Cimera R, et al. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases. Mod Pathol 2019;32:1329-43, doi:http://dx.doi.org/10.1038/s41379-019-0273-1.

[105] Swami U, Nussenzveig RH, Haaland B, Agarwal N. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Ann Transl Med 2019;7:S18, doi: http://dx.doi.org/10.21037/atm.2019.01.50.

[106] Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald J, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;69:93-99, doi:http://dx.doi.org/10.3322/caac.21388.

[107] Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol 2018;73:560-9, doi:http://dx.doi.org/10.1016/j.eurouro.2017.12.018.

[108] Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, et al. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol 2013;37:1505-17, doi:http://dx.doi.org/10.1097/PAS.0b013e318298a85do.

[109] Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490-504, doi:http://dx.doi.org/10.1097/PAS.0b013e3182990fb.

[110] Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, et al. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 2013;37:1518-31, doi:http://dx.doi.org/10.1097/PAS.0b013e31829912e.

[111] Verkarre V, Morini A, Denize T, Ferlicot S, Richard S. [Hereditary kidney cancers: the pathologist's view in 2020]. Ann Pathol 2020;40:148-67, doi:http://dx.doi.org/10.1016/j.annpat.2020.02.022.

[112] Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640, doi:http://dx.doi.org/10.1016/j.ctarc.2022.100640.

[113] Halabi S, Armstrong AJ. Sarcomatoid renal cell carcinoma: an immune checkpoint-responsive subset? Eur Urol 2021;79:663-4, doi:http://dx.doi.org/10.1016/j.eurouro.2021.01.042.

[114] Moualem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: biology and treatment advances. Urol Oncol 2018;36:265-71, doi:http://dx.doi.org/10.1016/j. urolonc.2017.12.012.

[115] Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78, doi:http://dx.doi.org/10.1038/s41585-020-00382-9.

[116] Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660-73, doi:http://dx.doi.org/10.1016/j.eurouro.2015.07.072.

[117] Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of renal masses and localized renal cancer. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.

[118] Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 2017;119:661-6, doi:http://dx.doi.org/10.1111/bju.13763.

[119] Branger N, Bigot P, Pignot G, Lorusso V, Audenet F, Parier B, et al. Oncocytoma on renal mass biopsy: is it still the same histology when surgery is performed? Results from UroCCR-104 study. World J Urol 2023;41:483-9, doi:http://dx.doi.org/10.1007/s00345-022-04261-3.

[120] Baboudjian M, Moser D, Yanagisawa T, Gondran-Tellier B, Compérat EM, Ambrosetti D, et al. Benefit and harm of active surveillance for biopsy-proven renal oncocytoma: a systematic review and pooled analysis. Eur Urol Open Sci 2022;41:8-15, doi: http://dx.doi.org/10.1016/j.euros.2022.04.009.

[121] Rodger FE, Brown K, Leung S, Coode-Bate J, Armitage J, Warren A, et al. Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance. BJUI Compass 2022;3:291-7, doi:http://dx.doi.org/10.1002/bco.2141.

[122] Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Lattouf J-B, et al. Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? J Urol 2018;200:731-6, doi:http://dx.doi.org/10.1016/j.juro.2018.04.015.

[123] Richard PO, Jewett MAS, Tanguay S, Saarela O, Liu ZA, Pouliot F, et al. Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry. BJU Int 2017;119:543-9, doi:http://dx.doi.org/10.1111/bju.13630.

[124] Posielski NM, Bui A, Wells SA, Best SL, Gettle LM, Ziemlewicz TJ, et al. Risk factors for complications and nondiagnostic results following 1155 consecutive percutaneous core renal mass biopsies. J Urol 2019;201:1080-7, doi:http://dx.doi.org/10.1097/JU.0000000000000113.

[125] Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660-73, doi:http://dx.doi.org/10.1016/j.eurouro.2015.07.072.

[126] Menogue SR, O'Brien BA, Brown AL, Cohen RJ. Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention. BJU Int 2013;111:E146-51, doi:http://dx.doi.org/10.1111/j.1464-410X.2012.11384.x.

[127] Amaral BS, Macek P, Arora A, Pazeto CL, Zugail AS, Mombet A, et al. Renal tumor biopsy: rationale to avoid surgery in small renal masses. Curr Urol Rep 2021;22:46, doi:http://dx.doi.org/10.1007/s11934-021-01064-8.

[128] Robert SC, Cossetto T, Miao TL, Li K, Habib E, Mocanu V, et al. Complications after renal mass biopsy: frequency, nature, timing, and associated characteristics. AJR Am J Roentgenol 2023;221:344-53, doi:http://dx.doi.org/10.2214/AJR.23.29059.

[129] Garbens A, Wallis CJD, Klaassen Z, Saskin R, Plumptre L, Kodama R, et al. Comprehensive assessment of the morbidity of renal mass biopsy: a population-based assessment of biopsy-related complications. Can Urol Assoc J 2021;15:42-7, doi: http://dx.doi.org/10.5489/cuaj.6477.

[130] Macklin PS, Sullivan ME, Tapping CR, Cranston DW, Webster GM, Roberts ISD, et al. Tumour seeding in the tract of percutaneous renal tumour biopsy: a report on seven cases from a UK tertiary referral centre. Eur Urol 2019;75:861-7, doi:http://dx.doi.org/10.1016/j.eurouro.2018.12.011.

[131] Staehler M, Rodler S, Brinkmann I, Steig CF, Graser A, Götz M, et al. Long-term follow-up in patients undergoing renal mass biopsy: seeding is not anecdotal. Clin Genitourin Cancer 2024;22:189-92, doi:http://dx.doi.org/10.1016/j.clgc.2023.10.012.

[132] Richard PO, Jewett MAS, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, et al. Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol 2015;68:1007-13, doi:http://dx.doi.org/10.1016/j.eurouro.2015.04.004.

[133] Vijay V, Vokshi FH, Smigelski M, Nagpal S, Huang WC. Incidence of benign renal masses in a contemporary cohort of patients receiving partial nephrectomy for presumed renal cell carcinoma. Clin Genitourin Cancer 2023;21:e114-8, doi:http://dx.doi.org/10.1016/j.clgc.2022.11.006 [S1558-7673(22)00240-3].

[134] Patel AK, Lane BR, Chintalapati P, Fouad L, Butaney M, Budzyn J, et al. Utilization of renal mass biopsy for T1 renal lesions across Michigan: results from MUSIC-KIDNEY. A statewide quality improvement collaborative. Eur Urol Open Sci 2021;30:37-43, doi:http://dx.doi.org/10.1016/j.euros.2021.06.004.

[135] Jasinski M, Siekiera J, Tworkiewicz M. Ultrasound-guided renal mass biopsy and its clinical utility: a single-centre experience. Urol Int 2022;106:560-6, doi:http://dx.doi.org/10.1159/000521153.

[136] Jiang P, Arada RB, Okhunov Z, Afyouni AS, Peta A, Brevik A, et al. Multidisciplinary approach and outcomes of pretreatment small (cT1a) renal mass biopsy: single-center experience. J Endourol 2022;36:703-11, doi:http://dx.doi.org/10.1089/end.2021.0664.

[137] Ferrari M, Cartolari R, Barizzi J, Pereira Mestre R, d'Antonio E, Renard J. Percutaneous biopsy of small renal mass: can diagnostic accuracy be affected by hospital volume? Cent European J Urol 2021;74:334-40, doi:http://dx.doi.org/10.5173/ceju.2021.3.0104.

[138] Okhunov Z, Gorin MA, Jefferson FA, Afyouni AS, Allaf ME, Pierorazio PM, et al. Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses? Urol Oncol 2021;39:735.e17-23, doi:http://dx.doi.org/10.1016/j.urolonc.2021.05.024.

[139] Lobo JM, Clements MB, Bitner DP, Mikula MD, Noona SW, Sultan MI, et al. Does renal mass biopsy influence multidisciplinary treatment recommendations? Scand J Urol 2020;54:27-32, doi:http://dx.doi.org/10.1080/21681805.2019.1703805.

[140] Couture F, Finelli T, Breau RH, Mallick R, Bhindi B, Tanguay S, et al. The increasing use of renal tumor biopsy amongst Canadian urologists: when is biopsy most utilized? Urol Oncol 2021;39:499.e15-22, doi:http://dx.doi.org/10.1016/j. urolonc.2021.05.026.

[141] Patel HD, Nichols PE, Su ZT, Gupta M, Cheaib JG, Allaf ME, et al. Renal mass biopsy is associated with reduction in surgery for early-stage kidney cancer. Urology 2020;135:76-81, doi:http://dx.doi.org/10.1016/j.urology.2019.08.043.

[142] Ali SN, Tano Z, Landman J. The changing role of renal mass biopsy. Urol Clin North Am 2023;50:217-25, doi:http://dx.doi.org/10.1016/j.ucl.2023.01.002.

[143] Sinks A, Miller C, Holck H, Zeng L, Gaston K, Riggs S, et al. Renal mass biopsy mandate is associated with change in treatment decisions. J Urol 2023;210:72-8, doi:http://dx.doi.org/10.1097/JU.00000000000003429.

[144] Prebay ZJ, Patel A, Johnson A, Kim T, Fonshell C, Raman JD, et al. Perspectives on the role of biopsy for management of T1 renal masses: survey results from two regional quality improvement collaboratives. Urology 2022;165:206-11, doi:http://dx.doi.org/10.1016/j.urology.2022.01.038 [S0090-4295(22)00093-0].

[145] Patel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, et al. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: a population-based study utilizing the National Cancer Database. Urol Oncol 2021;39:79.e1-8, doi:http://dx.doi.org/10.1016/j.urolonc.2020.10.015.

[146] Ozambela M, Wang Y, Leow JJ, Silverman SG, Chung BI, Chang SL. Contemporary trends in percutaneous renal mass biopsy utilization in the United States. Urol Oncol 2020;38:835-43, doi:http://dx.doi.org/10.1016/j. urolonc.2020.07.022.

[147] Michel J, Lenis AT, Lee PM, Golla V, Johnson DC, Gollapudi K, et al. Analysis of guideline recommended use of renal mass biopsy and association with treatment. Can J Urol 2020;27:10285-93.
[148] Pasquier D, Rozet F, Fregeville A, Barret E, Lanz C, Macek P, et al. Renal tumor biopsy does not increase the risk of surgical complications of minimally invasive partial nephrectomy. Prog Urol 2022;32:843-8, doi:http://dx.doi.org/10.1016/j.purol.2022.03.006.

[149] Shahait M, Jackman S, Landman J, Lechevallier E, Billiet I, Fossion L, et al. Utilization and operative influence of renal mass biopsy in the small renal mass: analysis from the Clinical Research Office of the Endoscopic Society Small Renal Mass registry. J Endourol 2020;34:99-106, doi:http://dx.doi.org/10.1089/end.2019.0297.

[150] Kunath F, Schmidt S, Krabbe LM, Miernik A, Dahm P, Cleves A, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev 2017;5:CD012045, doi:http://dx.doi.org/10.1002/146518585.CD012045.pub2.

[151] Van Poppel H, Da Pozzo L, Albrecht W, Matveey V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011;59:543-52, doi:http://dx.doi.org/10.1016/j.eururo.2010.12.013.

[152] Talenfeld AD, Gennarelli RL, Elkin EB, Atoria CL, Durack JC, Huang WC, et al. Percutaneous ablation versus partial and radical nephrectomy for T1a renal cancer: a population-based analysis. Ann Intern Med 2018;169:69-77, doi:http://dx.doi.org/10.7326/M17-0585.

[153] Jamil ML, Keeley J, Sood A, Dalela D, Arora S, Peabody JO, et al. Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the Eastern Cooperative Oncology Group - American College of Radiology Imaging Network E2805 Trial Cohort. Eur Urol 2020;77:277-81, doi:http://dx.doi.org/10.1016/j.eururo.2019.10.028.

[154] Bensalah K, Pantuck AJ, Riou-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, et al. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol 2010;57:466-71, doi: http://dx.doi.org/10.1016/j.eururo.2009.03.048.

[155] Bernhard J-C, Pantuck AJ, Wallerand H, Crepel M, Ferrière J-M, Bellec L, et al. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol 2010;57:1080-6, doi:http://dx.doi.org/10.1016/j.eururo.2010.02.019.

[156] Kim SP, Abouassaly R. Treatment of patients with positive margins after partial nephrectomy. J Urol 2016;196:301-2, doi:http://dx.doi.org/10.1016/j.juro.2016.05.078.

[157] Wood EL, Adibi M, Qiao W, Brandt J, Zhang M, Tamboli P, et al. Local tumor bed recurrence following partial nephrectomy in patients with small renal masses. J Urol 2018;199:393-400, doi:http://dx.doi.org/10.1016/j.juro.2017.09.072.

[158] Kriegmair MC, Bertolo R, Karakiewicz PI, Leibovitz BC, Ljungberg B, Mir MC, et al. Systematic review of the management of local kidney cancer relapse. Eur Urol Oncol 2018;1:512-23, doi:http://dx.doi.org/10.1016/j.euro.2018.06.007.

[159] Brassier M, Khene Z-E, Bernhard J-C, Dang VT, Ouzaïd I, Nouhaud FX, et al. Percutaneous ablation versus surgical resection for local recurrence following partial nephrectomy for renal cell cancer: a propensity score analysis (REPART Study-UroCCR 71). Eur Urol Focus 2022;8:210-6, doi:http://dx.doi.org/10.1016/j.euf.2021.02.007.

[160] Cosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014;65:372-7, doi:http://dx.doi.org/10.1016/j.eururo.2013.06.044.

[161] Miller DC, Schonlau M, Litwin MS, Lai J, Saigal CS. Urologic Diseases in America Project. Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer 2008;112:511-20, doi:http://dx.doi.org/10.1002/cncr.23218.

[162] Capitanio U, Terrone C, Antonelli A, Minervini A, Volpe A, Furlan M, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur Urol 2015;67:683-9, doi:http://dx.doi.org/10.1016/j.eururo.2014.09.027.

[163] Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors – is there a difference in mortality and cardiovascular outcomes? J Urol 2009;181:55-61, doi:http://dx.doi.org/10.1016/j.juro.2008.09.017 (discussion 61-62).

[164] Gratzke C, Seitz M, Bayrle F, Schlenker B, Bastian PJ, Haseke N, et al. Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU Int 2009;104:470-5, doi:http://dx.doi.org/10.1111/j.1464-410X.2009.08439.x.

[165] Huang WC, Donin NM, Levey AS, Campbell SC. Chronic kidney disease and kidney cancer surgery: new perspectives. J Urol 2020;203:475-85, doi:http://dx.doi.org/10.1097/JU.0000000000000326.

[166] Volpe A, Blute ML, Ficarra V, Gill IS, Kutikov A, Porpiglia F, et al. Renal ischemia and function after partial nephrectomy: a collaborative review of the literature. Eur Urol 2015;68:61-74, doi:http://dx.doi.org/10.1016/j.eururo.2015.01.025.

[167] Mir MC, Ercole C, Takagi T, Zhang Z, Velet L, Remer EM, et al. Decline in renal function after partial nephrectomy: etiology and prevention. J Urol 2015;193:1889-98, doi:http://dx.doi.org/10.1016/j.juro.2015.01.093.

[168] Zhang Z, Zhao J, Dong W, Remer E, Li J, Demirjian S, et al. Acute kidney injury after partial nephrectomy: role of parenchymal mass reduction and ischemia and impact on subsequent functional recovery. Eur Urol 2016;69:745-52, doi:http://dx.doi.org/10.1016/j.eururo.2015.10.023.

[169] Greco F, Autorino R, Altieri V, Campbell S, Ficarra V, Gill I, et al. Ischemia techniques in nephron-sparing surgery: a systematic review and meta-analysis of surgical, oncological, and functional outcomes. Eur Urol 2019;75:477-91, doi:http://dx.doi.org/10.1016/j.eururo.2018.10.005.

[170] Dong W, Wu J, Suk-Ouichai C, Caraballo Antonio E, Remer EM, Li J, et al. Ischemia and functional recovery from partial nephrectomy: refined perspectives. Eur Urol Focus 2018;4:572-8, doi:http://dx.doi.org/10.1016/j.euf.2017.02.001.

[171] Cignoli D, Basile G, Fallara G, Rosiello G, Belladelli F, Cei F, et al. Risks and benefits of partial nephrectomy performed with limited or with zero ischemia time. BJU Int 2023;132:283-90, doi:http://dx.doi.org/10.1111/bju.16009.

[172] Fong KY, Gan VHL, Lim BJH, Chan YH, Castellani D, Chen K, et al. Off-clamp vs. on-clamp robot-assisted partial nephrectomy: a systematic review and meta-analysis. BJU Int 2024;133:375-86, doi:http://dx.doi.org/10.1111/bju.16250.

[173] Mellouki A, Bentillers I, Morrone A, Doumerc N, Beauval J-B, Rouprit M, et al. Evaluation of oncological outcomes of robotic partial nephrectomy according to the type of hilar control approach (on-clamp vs. off-clamp), a multicentric study of the French network of research on kidney cancer-UROCCR 58-NCT03293563. World J Urol 2023;41:287-94, doi:http://dx.doi.org/10.1007/s00345-020-03558-5.

[174] Liu P, Li Y, Shi B, Zhang Q, Guo H. The outcome of sutureless in partial nephrectomy: a systematic review and meta-analysis. Biomed Res Int 2022;2022:5260131, doi: http://dx.doi.org/10.1155/2022/5260131.

[175] Introini C, Di Domenico A, Ennas M, Campodonico F, Brusasco C, Benelli A. Functional and oncological outcomes of 3D clampless sutureless laparoscopic partial nephrectomy for renal tumors with low morbidity score. Minerva Urol Nefrol 2020;72:723-8, doi:http://dx.doi.org/10.23736/S0393-2249.20.04005-9.

[176] Wu J, Suk-Ouichai C, Dong W, Zhang Z, Tanaka H, Wang Y, et al. Vascularized parenchymal mass preserved with partial nephrectomy: functional impact and predictive factors. Eur Urol Oncol 2019;2:97-103, doi:http://dx.doi.org/10.1016/j.eurol.2018.06.009.

[177] Cao D-H, Liu L-R, Fang Y, Tang P, Li T, Bai Y, et al. Simple tumor enucleation may not decrease oncologic outcomes for T1 renal cell carcinoma: a systematic review. Eur Urol Oncol 2017;35:661.e15-21, doi:http://dx.doi.org/10.1016/j. urolonc.2017.07.007.

[178] Bertolo R, Pecoraro A, Carbonara U, Amparore D, Diana P, Muselaers S, et al. Resection techniques during robotic partial nephrectomy: a systematic review. Eur Urol Open Sci 2023;5:22-7-21, doi:http://dx.doi.org/10.1016/j.euros.2023.03.008.

[179] Potretzke AM, Knight BA, Zargar H, Kaouk JH, Barod R, Rogers CG, et al. Urinary fistula after robot-assisted partial nephrectomy: a multicentre analysis of 1791 patients. BJU Int 2016;117:131-7, doi:http://dx.doi.org/10.1111/bju.13249.

[180] Khene Z, Peyronnet B, Freton L, Graffaille V, Pradere B, Robert C, et al. What is better for predicting morbidity of robotic partial nephrectomy – a score or your clinical judgement? Eur Urol Focus 2020;6:313-9, doi:http://dx.doi.org/10.1016/j.euf.2018.10.016.

[181] Simhan J, Sialdone MC, Tsai KJ, Canter DJ, Li T, Kutikov A, et al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur Urol 2011;60:724-30, doi:http://dx.doi.org/10.1016/j.eururo.2011.05.030.

[182] Khene Z-E, Mazouin C, Larcher A, Peyronnet B, Gasmi A, Roumiguïé M, et al. Predicting complications after robotic partial nephrectomy: back to simplicity. Eur Urol Focus 2022;8:777-83, doi:http://dx.doi.org/10.1016/j.euf.2021.04.017.

[183] Margue G, Ingels A, Bensalah K, Doumerc N, Vaessen C, Rouprit M, et al. Late complications and 5 years outcomes of robotic partial nephrectomy in France: prospective assessment in the French Kidney Cancer Research Network (UroCCR 10). World J Urol 2023;41:2281-8, doi:http://dx.doi.org/10.1007/s00345-023-04491-z.

[184] Chang KD, Abdel Raheem A, Kim KH, Oh CK, Park SY, Kim YS, et al. Functional and oncological outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years' follow-up. BJU Int 2018;122:618-26, doi:http://dx.doi.org/10.1111/bju.14250.

[185] Bravi CA, Larcher A, Capitanio U, Mari A, Antonelli A, Artibani W, et al. Perioperative outcomes of open, laparoscopic, and robotic partial nephrectomy: a prospective multicenter observational study (the RECORD2 Project). Eur Urol Focus 2021;7:390-6, doi:http://dx.doi.org/10.1016/j.euf.2019.10.013.

[186] Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR, et al. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:41-6, doi:http://dx.doi.org/10.1016/j.juro.2007.03.038.

[187] Guglielmetti GB, Dos Anjos GC, Sawczyn G, Rodrigues G, Cardili L, Cordeiro MD, et al. A prospective, randomized trial comparing the outcomes of open vs. laparoscopic partial nephrectomy. J Urol 2022;208:259-67, doi:http://dx.doi.org/10.1097/JU.00000000000002695.

[188] Panayotopoulos P, Bouvier A, Besnier L, Rousselet MC, Nedelcu C, Baize N, et al. Laparoscopic partial nephrectomy following tumor embolization in a hybrid room. Feasibility and clinical outcomes. Surg Oncol 2017;26:377-81, doi:http://dx.doi.org/10.1016/j.suronc.2017.07.012.

[189] Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, et al. Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol 2016;23:4277-83, doi:http://dx.doi.org/10.1245/s10434-016-5411-0.

[190] Ni Y, Yang X. A systematic review and meta-analysis of comparison of outcomes of robot-assisted versus open partial nephrectomy in clinical T1 renal cell carcinoma patients. Urol Int 2022;106:757-67, doi:http://dx.doi.org/10.1159/000521881.

[191] Masson-Lecomte A, Yates DR, Hupertan V, Haertig A, Chartier-Kastler E, Bitker M-O, et al. A prospective comparison of the pathologic and surgical outcomes obtained after elective treatment of renal cell carcinoma by open or robot-assisted partial nephrectomy. J Urol Oncol 2013;31:924-9, doi:http://dx.doi.org/10.1016/j. urolonc.2011.08.004.

[192] Bernhard J-C, Robert G, Ricard S, Michiels C, Capon G, Boulenger de Hautecloque A, et al. Day-case robotic-assisted partial nephrectomy: feasibility and preliminary results of a prospective evaluation (UroCCR-25 AMBU-REIN study). World J Urol 2022;40:1351-7, doi:http://dx.doi.org/10.1007/s00345-020-03283-z.
[193] Bernhard J-C, Robert G, Ricard S, Rogier J, Degryse C, Michiels C, et al. Nurse-led coordinated surgical care pathways for cost optimization of robotic-assisted partial nephrectomy: medico-economic analysis of the UroCCR-25 AMBU-REIN study. World J Urol 2023;41:325-33, doi:http://dx.doi.org/10.1007/s00345-022-04066-4.

[194] Choi JE, You JH, Kim DK, Rha KH, Lee SH. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. Eur Urol 2015;67:891-901, doi:http://dx.doi.org/10.1016/j.eururo.2014.12.028.

[195] Long J-A, Yakoubi R, Lee B, Guillotreau J, Autorino R, Laydner H, et al. Robotic versus laparoscopic partial nephrectomy for complex tumors: comparison of perioperative outcomes. Eur Urol 2012;61:1257-62, doi:http://dx.doi.org/10.1016/j.eururo.2012.03.012.

[196] Michiels C, Khene Z-E, Prudhomme T, Boulenger de Hauteclocque A, Cornelis FH, Percot M, et al. 3D-Image guided robotic-assisted partial nephrectomy: a multi-institutional propensity score-matched analysis (UroCCR study 51). World J Urol 2023;41:303-13, doi:http://dx.doi.org/10.1007/s00345-021-03645-1.

[197] Porpiglia F, Mari A, Amparore D, Fiori C, Antonelli A, Artibani W, et al. Transperitoneal vs. retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (the RECORD 2 Project). Surg Endosc 2021;35:4295-304, doi: http://dx.doi.org/10.1007/s00464-020-07919-4.

[198] Couapel J-P, Bensalah K, Bernhard J-C, Pignot G, Zini L, Lang H, et al. Is there a volume-outcome relationship for partial nephrectomy? World J Urol 2014;32:1323-9, doi:http://dx.doi.org/10.1007/s00345-013-1213-1.

[199] Peyronnet B, Tondut L, Bernhard J-C, Vaessen C, Doumerc N, Sebe P, et al. Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study. BJU Int 2018;121:916-22, doi:http://dx.doi.org/10.1111/bju.14175.

[200] Auffenberg GB, Curry M, Gennarelli R, Blum KA, Elkin E, Russo P. Comparison of cancer specific outcomes following minimally invasive and open surgical resection of early stage kidney cancer from a National Cancer Registry. J Urol 2020;203:1094-100, doi:http://dx.doi.org/10.1097/JU.00000000000000741.

[201] Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP. Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. J Urol 2007;177:862-6, doi:http://dx.doi.org/10.1016/j.juro.2006.10.053.

[202] Wang L, Li K, Yin S, Yang L, Zhu P. Oncologic and perioperative outcomes of laparoscopic versus open radical nephrectomy for the treatment of renal tumor (> 7 cm): a systematic review and pooled analysis of comparative outcomes. World J Surg Oncol 2023;21:35, doi:http://dx.doi.org/10.1186/s12957-023-02916-y.

[203] Desai MM, Strzempekowski B, Matin SF, Steinberg AP, Ng C, Meraney AM, et al. Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy. J Urol 2005;173:38-41, doi:http://dx.doi.org/10.1097/01.ju.0000145886.26719.73.

[204] Hemal AK, Kumar A. A prospective comparison of laparoscopic and robotic radical nephrectomy for T1-2N0M0 renal cell carcinoma. World J Urol 2009;27:89-94, doi: http://dx.doi.org/10.1007/s00345-008-0321-9.

[205] Uhlig J, Strauss A, Rücker G, Seif Amir Hosseini A, Lotz J, Trojan L, et al. Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis. Eur Radiol 2019;29:1293-307, doi:http://dx.doi.org/10.1007/s00330-018-5660-3.

[206] Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Oncologic outcomes following partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2019;76:244-51, doi:http://dx.doi.org/10.1016/j.euro.2019.04.026.

[207] Larcher A, Fossati N, Mistretta F, Lughezzani G, Lista G, Dell'Oglio P, et al. Long-term oncologic outcomes of laparoscopic renal cryoablation as primary treatment for small renal masses. Urol Oncol 2015;33:22.e1-9, doi:http://dx.doi.org/10.1016/j. urolonc.2014.09.003.

[208] Abu-Ghanem Y, Fernández-Pello S, Bex A, Ljungberg B, Albiges L, Dabestani S, et al. Limitations of available studies prevent reliable comparison between tumour ablation and partial nephrectomy for patients with localised renal masses: a systematic review from the European Association of Urology Renal Cell Cancer Guideline Panel. Eur Urol Oncol 2020;3:433-52, doi:http://dx.doi.org/10.1016/j. euro.2020.02.001.

[209] Cazalas G, Klein C, Piana G, De Kerviler E, Gangi A, Puech P, et al. A multicenter comparative matched-pair analysis of percutaneous tumor ablation and robotic-assisted partial nephrectomy of T1b renal cell carcinoma (AblatT1b study-UroCCR 80). Eur Radiol 2023;33:6513-21, doi:http://dx.doi.org/10.1007/s00330-023- 09564-6.

[210] Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, Shariat SF, et al. Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pT1b kidney cancer. J Urol 2019;202:1120-6, doi:http://dx.doi.org/10.1097/JU.00000000000000460.

[211] Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, et al. Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2017;12:1057-69, doi:http://dx.doi.org/10.2215/CJN.1194116.

[212] Pantelidou M, Challacombe B, McGrath A, Brown M, Ilyas S, Katsanos K, et al. Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma. Cardiovasc Intervent Radiol 2016;39:1595-603, doi:http://dx.doi.org/10.1007/s00270-016-1417-z.

[213] Chang X, Zhang F, Liu T, Ji C, Zhao X, Yang R, et al. Radio frequency ablation versus partial nephrectomy for clinical T1b renal cell carcinoma: long-term clinical and

oncologic outcomes. J Urol 2015;193:430-5, doi:http://dx.doi.org/10.1016/j. juro.2014.07.112.

[214] Yu J, Zhang X, Liu H, Zhang R, Yu X, Cheng Z, et al. Percutaneous microwave ablation versus laparoscopic partial nephrectomy for cT1a renal cell carcinoma: a propensity-matched cohort study of 1955 patients. Radiology 2020;294:698-706, doi:http://dx. doi.org/10.1148/radiol.2020190919.

[215] Breen DJ, King AJ, Patel N, Lockyer R, Hayes M. Image-guided cryoablation for sporadic renal cell carcinoma: three- and 5-year outcomes in 220 patients with biopsy-proven renal cell carcinoma. Radiology 2018;289:554-61, doi:http://dx.doi. org/10.1148/radiol.2018180249.

[216] Katsanos K, Mailli L, Krokidis M, McGrath A, Sabharwal T, Adam A. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol 2014;37:427-37, doi:http://dx.doi.org/ 10.1007/s00270-014-0846-9.

[217] Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol 2017;40:177-91, doi:http://dx.doi.org/10.1007/s00270-016-1531-y.

[218] Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, et al. The role of stereotactic ablative body radiotherapy in renal cell carcinoma. Eur Urol 2022;82:613-22, doi:http://dx.doi.org/10.1016/j.eururo.2022.06.017.

[219] Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, et al. The emerging role of stereotactic ablative radiotherapy for frail patients with primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus 2019;5:958-69, doi:http://dx. doi.org/10.1016/j.euf.2019.06.002.

[220] Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int 2017;120:623-30, doi:http://dx.doi.org/10.1111/bju.13811.

[221] Siva S, Louie AV, Kotecha R, Barber MN, Ali M, Zhang Z, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol 2024;25:e18-28, doi:http://dx.doi.org/10.1016/S1470-2045(23)00513-2.

[222] Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, et al. Consensus statement from the International Radiosurgery Oncology Consortium for kidney for primary renal cell carcinoma. Future Oncol 2016;12:637-45, doi:http://dx.doi.org/ 10.2217/fon.16.2.

[223] Grelier L, Baboudjian M, Gondran-Tellier B, Couderc A-L, McManus J, Deville J-L, et al. Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience. Cancers (Basel) 2021;13:3129, doi:http://dx.doi.org/10.3390/cancers13133129.

[224] Glicksman RM, Cheung P, Korol R, Niglas M, Nusrat H, Erler D, et al. Stereotactic body radiotherapy for renal cell carcinoma: oncological and renal function outcomes. Clin Oncol (R Coll Radiol) 2023;35:20-8, doi:http://dx.doi.org/10.1016/ j.clon.2022.06.007.

[225] Grubb WR, Ponsky L, Lo SS, Kharouta M, Traubiger M, Sandstrom K, et al. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol 2021;155:43-43, doi:http://dx.doi.org/10.1016/j.radonc.2020.10.031.

[226] Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, Wel AM, et al. The role of daily adaptive stereotactic MR-guided radiotherapy for primary kidney cancer. Cancers (Basel) 2020;12:2763, doi:http://dx.doi.org/10.3390/cancers12102763.

[227] Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, et al. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised 2 trial. Lancet Oncol 2024;25:308-16, doi:http://dx.doi.org/ 10.1016/S1470-2045(24)00020-2.

[228] Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste B, Davey R, et al. TROG 15.03/ ANZUP international multicenter phase II trial of Focal Ablative Stereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II). Int J Radiat Oncol Biol Phys 2023;117:S3, doi:http://dx.doi.org/10.1016/j.jirobp.2023.06.208.

[229] Bentahila R, Bensalah K, Benziane-Ouaritini N, Barthelemy P, Rioux-Leclerc N, Correas J-M, et al. Stereotactic body radiation therapy for primary renal cell carcinoma: a review on behalf of the CC AFU. Fr J Urol 2024;34:102660, doi:http:// dx.doi.org/10.1016/j.fjurol.2024.102660.

[230] Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, et al. Role of active surveillance for localized small renal masses. Eur Urol Oncol 2018;1:177-87, doi:http://dx.doi.org/10.1016/j.euo.2018.05.001.

[231] Jewett MAS, Mattar K, Basiuk J, Morash CG, Pautler SE, Siemans DR, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011;60:39-44, doi:http://dx.doi.org/10.1016/j.eururo.2011.03.030.

[232] Uosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, et al. Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry. J Urol 2018;199:641-8, doi:http://dx.doi.org/10.1016/j. juro.2017.09.087.

[233] Klatte T, Berni A, Serni S, Campi R. Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. BJU Int 2021;128:131-43, doi:http://dx.doi.org/10.1111/ bju.15435.

[234] Finelli A, Cheung DC, Al-Matar A, Evans AJ, Morash CG, Pautler SE, et al. Small renal mass surveillance: histology-specific growth rates in a biopsy-characterized cohort. Eur Urol 2020;78:460-7, doi:http://dx.doi.org/10.1016/j.eururo.2020.06.053.

[235] Sialdone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DYT, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012;118:997-1006, doi:http://dx.doi.org/10.1002/ cnrc.26369.

[236] Pierorazio PM, Johnson MH, Ball MW, Gorin MA, Trock BJ, Chang P, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and
surveillance for small renal masses: the DISSRM registry. Eur Urol 2015;68:408–15, doi:http://dx.doi.org/10.1016/j.eururo.2015.02.001.

[237] Metcalf MR, Cheaib JG, Biles MJ, Patel HD, Peña VN, Chang P, et al. Outcomes of active surveillance for young patients with small renal masses: prospective data from the DISSRM registry. J Urol 2021;205:1286–93, doi:http://dx.doi.org/10.1097/JU.00000000000001575.

[238] Alam R, Patel HD, Osumah T, Srivastava A, Gorin MA, Johnson MH, et al. Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU Int 2019;123:42–50, doi:http://dx.doi.org/10.1111/bju.14490.

[239] Petros FG, Venkatesan AM, Kaya D, Ng CS, Fellman BM, Karam JA, et al. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int 2019;123:447–55, doi:http://dx.doi.org/10.1111/bju.14486.

[240] Patel N, Cranston D, Akhtar MZ, George C, Jones A, Leiblich A, et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 2012;110:1270–5, doi:http://dx.doi.org/10.1111/j.1464-410X.2012.11130.x.

[241] Goldberg H, Ajaj R, Cáceres JOH, Berlin A, Chandrasekhar K, Klaassen Z, et al. Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. Urol Oncol 2020;38:603.e17–25, doi:http://dx.doi.org/10.1016/j.urolonc.2020.02.015.

[242] Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, et al. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: a 2-year prospective study. Eur Urol 2013;63:1122–7, doi:http://dx.doi.org/10.1016/j.eururo.2013.01.034.

[243] Pierorazio P, McKiernan J, Allaf M. 633 quality of life on active surveillance for a small renal masses versus immediate intervention: interim analysis of the disrm (delayed intervention and surveillance for small renal masses) registry. J Urol 2013;189:e259, doi:http://dx.doi.org/10.1016/j.juro.2013.02.185.

[244] Lee HJ, Liss MA, Derweesh IH. Outcomes of partial nephrectomy for clinical T1b and T2 renal tumors. Curr Opin Urol 2014;24:448–52, doi:http://dx.doi.org/10.1097/MOU.0000000000000081.

[245] Mir MC, Derweesh I, Porpiglia F, Zargar H, Mottrie A, Autorino R. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: a systematic review and meta-analysis of comparative studies. Eur Urol 2017;71:606–17, doi:http://dx.doi.org/10.1016/j.eururo.2016.08.060.

[246] Borghesi M, Schiavina R, Gan M, Novara G, Mottrie A, Ficarra V. Expanding utilization of robotic partial nephrectomy for clinical T1b and complex T1a renal masses. World J Urol 2013;31:499–504, doi:http://dx.doi.org/10.1007/s00345-013-1095-2.

[247] Klett DE, Tsivian M, Packiam VT, Lohse CM, Ahmed ME, Potretzke TA, et al. Partial versus radical nephrectomy in clinical T2 renal masses. Int J Urol 2021;28:1149–54, doi:http://dx.doi.org/10.1111/iju.14664.

[248] Huang R, Zhang C, Wang X, Hu H. Partial nephrectomy versus radical nephrectomy for clinical T2 or higher stage renal tumors: a systematic review and meta-analysis. Front Oncol 2021;11:680842, doi:http://dx.doi.org/10.3389/fonc.2021.680842.

[249] Janssen MWW, Linxweiler J, Terwey S, Rugge S, Ohlmann C-H, Becker F, et al. Survival outcomes in patients with large (≥7 cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: results of a multicenter cohort with long-term follow-up. PLoS One 2018;13:e0196427, doi:http://dx.doi.org/10.1371/journal.pone.0196427.

[250] Patel SH, Uzzo RG, Larcher A, Peyronnet B, Lane BR, Pruthi D, et al. Oncologic and functional outcomes of radical and partial nephrectomy in pT3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis. Clin Genitourin Cancer 2020;18:e723–9, doi:http://dx.doi.org/10.1016/j.clgc.2020.05.002.

[251] Boulenger de Hautecloque A, Ferrer L, Ambrosetti D, Ricard S, Bigot P, Bensalah K, et al. Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15). BJU Int 2023;132:160–9, doi:http://dx.doi.org/10.1111/bju.15959.

[252] Shah PH, Moreira DM, Patel VR, Gaunay G, George AK, Alom M, et al. Partial nephrectomy is associated with higher risk of relapse compared with radical nephrectomy for clinical stage T1 renal cell carcinoma pathologically up staged to T3a. J Urol 2017;198:289–96, doi:http://dx.doi.org/10.1016/j.juro.2017.03.012.

[253] Liu H, Kong Q-F, Li J, Wu Y-Q, Pan K-H, Xu B, et al. A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma. Transl Androl Urol 2021;10:1170–8, doi:http://dx.doi.org/10.21037/tau-20-1262.

[254] Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009;182:844–53, doi:http://dx.doi.org/10.1016/j.juro.2009.05.035.

[255] Kopp RP, Liss MA, Mehrazin R, Wang S, Lee HJ, Jabaji R, et al. Analysis of renal functional outcomes after radical or partial nephrectomy for renal masses ≥7 cm using the RENAL score. Urology 2015;86:312–9, doi:http://dx.doi.org/10.1016/j.urology.2015.02.067.

[256] Kopp RP, Mehrazin R, Palazzi KL, Liss MA, Jabaji R, Mirheydar HS, et al. Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score. BJU Int 2014;114:708–18, doi:http://dx.doi.org/10.1111/bju.12580.

[257] Srivastava A, Patel HD, Joice GA, Semerjian A, Gorin MA, Johnson MH, et al. Incidence of T3a up-staging and survival after partial nephrectomy: size-stratified rates and implications for prognosis. Urol Oncol 2018;36:12.e7–12.e13, doi:http://dx.doi.org/10.1016/j.urolonc.2017.09.005.

[258] Wang Y, Shao J, Ma X, Du Q, Gong H, Zhang X. Robotic and open partial nephrectomy for complex renal tumors: a matched-pair comparison with a long-term follow-up. World J Urol 2017;35:73–80, doi:http://dx.doi.org/10.1007/s00345-016-1849-8.

[259] Garisto J, Bertolo R, Dagenais J, Sagalovich D, Fareed K, Fergany A, et al. Robotic versus open partial nephrectomy for highly complex renal masses: comparison of perioperative, functional, and oncological outcomes. Urol Oncol 2018;36:471.e1–9, doi:http://dx.doi.org/10.1016/j.urolonc.2018.06.012.

[260] Hinau N, Shiroki R, Tanabe K, Eto M, Takenaka A, Kawakita M, et al. Robot-assisted partial nephrectomy versus standard laparoscopic partial nephrectomy for renal hilar tumor: a prospective multi-institutional study. Int J Urol 2021;28:382–9, doi: http://dx.doi.org/10.1111/iju.14469.

[261] Bradshaw AW, Autorino R, Simone G, Yang B, Uzzo RG, Porpiglia F, et al. Robotic partial nephrectomy vs. minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU Int 2020;126:114–23, doi: http://dx.doi.org/10.1111/bju.15064.

[262] Dursun F, Elshabrawy A, Wang H, Rodriguez R, Liss MA, Kaushik D, et al. Survival after minimally invasive vs. open radical nephrectomy for stage I and II renal cell carcinoma. Int J Clin Oncol 2022;27:1068–76, doi:http://dx.doi.org/10.1007/s10147-022-02153-5.

[263] Ebbing J, Wiebach T, Kempkensteffen C, Miller K, Bachmann A, Günzel K, et al. Evaluation of perioperative complications in open and laparoscopic surgery for renal cell cancer with tumor thrombus involvement using the Clavien-Dindo classification. Eur J Surg Oncol 2015;41:941–52, doi:http://dx.doi.org/10.1016/j.eurojso.2015.02.009.

[264] MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TBL, Hilvano-Cabungcal AM, et al. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol 2012;62:1097–117, doi: http://dx.doi.org/10.1016/j.eururo.2012.07.028.

[265] Li J, Peng L, Cao D, Cheng G, Bou H, Li Y, et al. Comparison of perioperative outcomes of robot-assisted vs. laparoscopic radical nephrectomy: a systematic review and meta-analysis. Front Oncol 2020;10:551052, doi:http://dx.doi.org/10.3389/fonc.2020.551052.

[266] Asimakopoulos AD, Miano R, Annino F, Micali S, Spera E, Iorio B, et al. Robotic radical nephrectomy for renal cell carcinoma: a systematic review. BMC Urol 2014;14:75, doi:http://dx.doi.org/10.1186/1471-2490-14-75.

[267] Anele UA, Marchioni M, Yang B, Simone G, Uzzo RG, Lau C, et al. Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA Collaborative Group). World J Urol 2019;37:2439–50, doi:http://dx.doi.org/10.1007/s00345-019-02657-2.

[268] Jeong IG, Khandwala YS, Kim JH, Han DH, Li S, Wang Y, et al. Association of robotic-assisted vs. laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015. JAMA 2017;318:1561–8, doi:http://dx.doi.org/10.1001/jama.2017.14586.

[269] Lane BR, Tiong H-Y, Campbell SC, Fergany AF, Weight CJ, Larson BT, et al. Management of the adrenal gland during partial nephrectomy. J Urol 2009;181:2430–6, doi:http://dx.doi.org/10.1016/j.juro.2009.02.027 [discussion 2436–2437].

[270] Bekema HJ, MacLennan S, Imamura M, Lam TBL, Stewart F, Scott N, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013;64:799–810, doi:http://dx.doi.org/10.1016/j.eururo.2013.04.033.

[271] Capitanio U, Guardi N, Matloob R, Roscigno M, Abdollah F, Di Trapani E, et al. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). BJU Int 2014;114:210–5, doi:http://dx.doi.org/10.1111/bju.12508.

[272] John NT, Blum KA, Hakimi AA. Role of lymph node dissection in renal cell cancer. Urol Oncol 2019;37:187–92, doi:http://dx.doi.org/10.1016/j. urolonc.2018.03.006.

[273] Gershman B, Thompson RH, Boorjian SA, Larcher A, Capitanio U, Montorsi F, et al. Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis. J Urol 2018;199:1143–8, doi:http://dx.doi.org/10.1016/j.juro.2017.11.114.

[274] Whitson JM, Harris CR, Reese AC, Meng MV. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol 2011;185:1615–20, doi:http://dx.doi.org/10.1016/j.juro.2010.12.053.

[275] Blom JHM, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28–34, doi:http://dx.doi.org/10.1016/j.eururo.2008.09.052.

[276] May M, Brookman-Amissah S, Pflanz S, Roigas J, Hoschke B, Kendel F. Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma. Br J Radiol 2009;82:724–31, doi:http://dx.doi.org/10.1259/bjr/17514226.

[277] Maxwell NJ, Saleem Amer N, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolisation in the palliative treatment of renal carcinoma. Br J Radiol 2007;80:96–102, doi:http://dx.doi.org/10.1259/bjr/31311739.

[278] Shapiro DD, Wells SA, Best SL, Hedican SP, Ziemlewicz TJ, Lubner MG, et al. Comparing outcomes for patients with clinical T1b renal cell carcinoma treated with either percutaneous microwave ablation or surgery. Urology 2020;135:88–94, doi: http://dx.doi.org/10.1016/j.urology.2019.09.024.

[279] Hasegawa T, Yamanaka T, Gobara H, Miyazaki M, Takaki H, Sato Y, et al. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol 2018;36:551–8, doi:http://dx.doi.org/10.1007/s11604-018-0756-x.

[280] Yanagisawa T, Mori K, Kawada T, Motlagh RS, Mostafaei H, Quhal F, et al. Differential efficacy of ablation therapy versus partial nephrectomy between clinical
T1a and T1b renal tumors: a systematic review and meta-analysis. Urol Oncol 2022;40:315-30, doi:http://dx.doi.org/10.1016/j.urolonc.2022.04.002.

[281] Schmit GD, Atwell TD, Callstrom MR, Farrell MA, Leibovich BC, Patterson DE, et al. Percutaneous cryoablation of renal masses > or = 3 cm: efficacy and safety in treatment of 108 patients. J Endourol 2010;24:1255-62, doi:http://dx.doi.org/10.1089/end.2009.0328.

[282] Atwell TD, Farrell MA, Callstrom MR, Charbonneau JW, Leibovich BC, Frank I, et al. Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 2007;188:1195-200, doi:http://dx.doi.org/10.2214/AJR.06.1152.

[283] Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L, et al. Stereotactic ablative radiotherapy for ≥ T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys 2020;108:941-9, doi:http://dx.doi.org/10.1016/j.ijrobp.2020.06.014.

[284] Almdal T, Sundqvist P, Harmenberg U, Hellström M, Lindskog M, Lindblad P, et al. Clinical T1a renal cell carcinoma, not always a harmless disease - a national register study. Eur Urol Open Sci 2022;39:22-8, doi:http://dx.doi.org/10.1016/j.euros.2022.03.005.

[285] Boulenger de Hauteclocque A, Ferrer L, Ambrosetti D, Ricard S, Bigot P, Bensalah K, et al. Machine-learning approach for prediction of pT3a upstaging and outcomes of localized renal cell carcinoma (UroCCR-15). BJU Int 2023;132:160-9, doi:http://dx.doi.org/10.1111/bju.15959.

[286] Vecchia A, Falagario U, Martini A, Marchioni M, Antonelli A, Simeone C, et al. Upstaging to pT3a in patients undergoing partial or radical nephrectomy for cT1 renal tumors: a systematic review and meta-analysis of outcomes and predictive factors. Eur Urol Focus 2021;7:574-81, doi:http://dx.doi.org/10.1016/j.euf.2020.05.013.

[287] Guo S, Liu Z, Li X, Yao K, Dong P, Chen D, et al. The prognostic value of the site of invasion in T3aN0M0 clear cell renal cell carcinoma. Urol Oncol 2019;37:301.e11-7, doi:http://dx.doi.org/10.1016/j.urolonc.2019.01.019.

[288] Wagner B, Patard J-J, Méjean A, Bensalah K, Verhoest G, Zigeuner R, et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol 2009;55:452-9, doi:http://dx.doi.org/10.1016/j.euro.2008.07.053.

[289] Martínez-Salamanca JI, Huang WC, Millán I, Bertini R, Bianco FJ, Carballido JA, et al. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension. Eur Urol 2011;59:120-7, doi:http://dx.doi.org/10.1016/j.eururo.2010.10.001.

[290] Zini L, Perrotte P, Jeldres C, Capitano U, Pharan D, Arjane P, et al. Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma. BJU Int 2008;102:1610-4, doi:http://dx.doi.org/10.1111/j.1464-410X.2008.07917.x.

[291] Bragraylan AC, Abbotoy D, Attwood K, Darwiche F, Hoffmeyer J, Kauffman EC, et al. Outcomes of minimal invasive vs. open radical nephrectomy for the treatment of locally advanced renal cell carcinoma. J Endourol 2016;30:871-6, doi:http://dx.doi.org/10.1089/end.2016.0082.

[292] Verhoest G, Couapel J-P, Oger E, Rioux-Leclercq N, Pignot G, Patard J-J, et al. Safety and feasibility of laparoscopic nephrectomy for big tumors (≥ 10 cm): a retrospective multicentric study. Clin Genitourin Cancer 2016;14:e335-40, doi:http://dx.doi.org/10.1016/j.clgc.2016.01.007.

[293] Becher E, Jericevic D, Huang WC. Minimally invasive surgery for patients with locally advanced and/or metastatic renal cell carcinoma. Urol Clin North Am 2020;47:389-97, doi:http://dx.doi.org/10.1016/j.ucln.2020.04.004.

[294] Blom JHM, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34, doi:http://dx.doi.org/10.1016/j.eururo.2008.09.052.

[295] Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma. N Engl J Med 2015;373:1814-23, doi:http://dx.doi.org/10.1056/NEJMoa1510016.

[296] Bekema HJ, MacLennan S, Imamura M, Lam TBL, Stewart F, Scott N, et al. Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. Eur Urol 2013;64:799-810, doi:http://dx.doi.org/10.1016/j.eururo.2013.04.033.

[297] Gershman B, Thompson RH, Moreira DM, Boorjian SA, Tollefson MK, Lohse CM, et al. Radical nephrectomy with or without lymph node dissection for nonmetastatic renal cell carcinoma: a propensity score-based analysis. Eur Urol 2017;71:560-7, doi: http://dx.doi.org/10.1016/j.eururo.2016.09.019.

[298] Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990;144:243-5, doi:http://dx.doi.org/10.1016/s0022-5347 (17)39422-3.

[299] Bhindi B, Wallis CJD, Boorjian SA, Thompson RH, Farrell A, Kim SP, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis. BJU Int 2018;121:684-98, doi:http://dx.doi.org/10.1111/bju.14127.

[300] Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, et al. Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol 2021;80:20-31, doi:http://dx.doi.org/10.1016/j.eururo.2021.02.025.

[301] Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5, doi:http://dx.doi.org/10.1016/j.eururo.2010.09.034.

[302] Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal

cell carcinoma. Eur Urol 2014;66:874-80, doi:http://dx.doi.org/10.1016/j.eururo.2014.01.035.

[303] Lebacle C, Bensalah K, Bernhard J-C, Albiges L, Laguerre B, Gross-Goupil M, et al. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. BJU Int 2019;123:804-10, doi:http://dx.doi.org/10.1111/bju.14581.

[304] Zhu M, Liu Z, Zhou Y, Jiang Z, Chen S, Wang W, et al. Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: a systematic review and meta-analysis. Oncol Lett 2024;27:162, doi:http://dx.doi.org/10.3892/ol.2024.14295.

[305] Gorin MA, Patent HD, Rowe SP, Hahn NM, Hammers HJ, Pons A, et al. Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma. Eur Urol 2022;5:113-7, doi:http://dx.doi.org/10.1016/j.euro.2021.04.002.

[306] Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol 2022;81:266-71, doi:http://dx.doi.org/10.1016/j.eururo.2021.10.001.

[307] Carlo MI, Attalla K, Mazaheri Y, Gupta S, Yildirim O, Murray SJ, et al. Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy. Eur Urol 2022;81:5870-3, doi:http://dx.doi.org/10.1016/j.eururo.2022.01.043 [S0302-2838(22)00086-0].

[308] Gu L, Peng C, Li H, Jia T, Chen X, Wang H, et al. Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2024;196:104316, doi:http://dx.doi.org/10.1016/j.critrevonc.2024.104316.

[309] Stewart G, Johnson L, Ganesh H, Davenport D, Smelser W, Crispen P, et al. Stone size limits the use of hounsfield units for prediction of calcium oxalate stone composition. Urology 2015;85:295-305, doi:http://dx.doi.org/10.1016/j.urology.2014.10.006.

[310] Westerman ME, Shapiro DD, Wood CG, Karam JA. Neoadjuvant therapy for locally advanced renal cell carcinoma. Urol Clin North Am 2020;47:329-43, doi:http://dx.doi.org/10.1016/j.ucln.2020.04.010.

[311] Leow JJ, Ray S, Dason S, Singer EA, Chang SL. The promise of neoadjuvant and adjuvant therapies for renal cancer. Urol Clin North Am 2023;50:285-303, doi: http://dx.doi.org/10.1016/j.ucln.2023.01.011.

[312] Tanaka H, Ding X, Ye Y, Wang Y, Campbell RA, DeWitt-Foy ME, et al. Infiltrative renal masses: clinical significance and fidelity of documentation. Eur Urol Oncol 2021;4:264-73, doi:http://dx.doi.org/10.1016/j.euo.2019.07.015.

[313] Borregales LD, Kim DY, Staller AL, Qiao W, Thomas AZ, Adibi M, et al. Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urol Oncol 2016;34:237.e19-26, doi:http://dx.doi.org/10.1016/j.urolonc.2015.11.020.

[314] Capitano U, Perrotte P, Zini L, Jeldres C, Shariat SF, Isbarn H, et al. Nephrectomy improves survival in patients with invasion of visceral and absence of nodal metastases (stage T4N0 renal cell carcinoma). BJU Int 2009;104:795-9, doi:http://dx.doi.org/10.1111/j.1464-410X.2009.08048.x.

[315] Margulis V, Sánchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer 2007;109:2025-30, doi:http://dx.doi.org/10.1002/cncr.22629.

[316] Bigot P, Barthelemy P, Boissier R, Khene Z-E, Pettenati C, Bernhard J-C, et al. French AFU Cancer Committee Guidelines - update 2022-2024: management of kidney cancer. Prog Urol 2022;32:1195-274, doi:http://dx.doi.org/10.1016/j.purol.2022.07.146.

[317] Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol 2013;31:1305-9, doi:http://dx.doi.org/10.1016/j.urolonc.2011.12.006.

[318] Cost NG, Delacrox SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011;59:912-8, doi:http://dx.doi.org/10.1016/j.eururo.2011.02.032.

[319] Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, et al. A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). Br J Cancer 2022;127:1051-60, doi:http://dx.doi.org/10.1038/s41416-022-01883-7.

[320] Agohukwu N, Shuch B. Clinical management of renal cell carcinoma with venous tumor thrombus. World J Urol 2014;32:581-9, doi:http://dx.doi.org/10.1007/s00345-014-1276-7.

[321] Psutka SP, Boorjian SA, Thompson RH, Schmit GD, Schmitz JJ, Bower TC, et al. Clinical and radiographic predictors of the need for inferior vena cava resection during nephrectomy for patients with renal cell carcinoma and caval tumor thrombus. BJU Int 2015;116:388-96, doi:http://dx.doi.org/10.1111/bju.13005.

[322] Gohji K, Yamashita C, Ueno K, Shimogaki H, Kamidono S. Preoperative computerized tomography detection of extensive invasion of the inferior vena cava by renal cell carcinoma: possible indication for resection with partial cardiopulmonary bypass and patch grafting. J Urol 1994;152:1993-6, doi:http://dx.doi.org/10.1016/s0022-5347(17)32288-7 [discussion 1997].

[323] Smith RK, Navaratnam A, Vivian P. Systematic review and meta-analysis of preoperative imaging prediction of renal cell carcinoma tumour thrombus inferior vena cava wall invasion. Clin Radiol 2023;78:540-7, doi:http://dx.doi.org/10.1016/j.crad.2023.02.022.

[324] Lawrentschuk N, Gani J, Riordan R, Esler S, Bolton DM. Multidetector computed tomography vs. magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review. BJU Int 2005;96:291-5, doi: http://dx.doi.org/10.1111/j.1464-410X.2005.05617.x.

[325] Shirodkar SP, Soloway MS, Ciancio G. Budd-Chiari syndrome in urology: impact on nephrectomy for advanced renal cell carcinoma. Indian J Urol 2011;27:351-6, doi: http://dx.doi.org/10.4103/0970-1591.85439.
[326] Garg H, Psutka SP, Hakimi AA, Kim HL, Mansour AM, Pruthi DK, et al. A decade of robotic-assisted radical nephrectomy with inferior vena cava thrombectomy: a systematic review and meta-analysis of perioperative outcomes. J Urol 2022;208:542–60, doi:http://dx.doi.org/10.1097/JU.0000000000002829.

[327] Shi T, Huang Q, Liu K, Du S, Fan Y, Yang L, et al. Robot-assisted cavity versus thrombectomy for level II inferior vena cava thrombus: decision-making scheme and multi-institutional analysis. Eur Urol 2020;78:592–602, doi:http://dx.doi.org/10.1016/j.eurour.2020.03.020.

[328] Abaza R, Eun DD, Gallucci M, Gill IS, Menon A, Mottrie A, et al. Robotic surgery for renal cell carcinoma with vena cava tumor thrombus. Eur Urol Focus 2016;2:601–7, doi:http://dx.doi.org/10.1016/j.euf.2017.01.001.

[329] Gill IS, Metcalfe C, Abrue A, Duddalwar V, Chopra S, Cunningham M, et al. Robotic level III inferior vena cava tumor thrombectomy: initial series. J Urol 2015;194:929–38, doi:http://dx.doi.org/10.1016/j.juro.2015.03.119.

[330] Baboudjian M, Gondran-Tellier B, Khene Z, Bigot P, Mejean A, Lang H, et al. Predictive factors of recurrence after surgery in patients with non-metastatic renal cell carcinoma with venous tumor thrombus (UroCCR-56 study). World J Urol 2023;41:295–302, doi:http://dx.doi.org/10.1007/s00345-021-03640-6.

[331] Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:683–94, doi:http://dx.doi.org/10.1056/NEJMoa2106391.

[332] Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeondes SN, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23:1133–44, doi:http://dx.doi.org/10.1016/S1470-2045(22)00487-9.

[333] Fleury R, Bertail T, Bensalah K, Bernhard J-C, Audenet F, Waeckel T, et al. The impact of histological variants on oncological outcomes after surgical resection of a nonmetastatic renal cell carcinoma with tumor thrombus: a multi-institutional study. Eur Urol Open Sci 2024;6:123–30, doi:http://dx.doi.org/10.1016/j.euros.2024.02.015.

[334] Yang Q, Meng F, Li K, Wang T, Nie Q, Che Z, et al. Safety and efficacy of thermal ablation for small renal masses in solitary kidney: evidence from meta-analysis of comparative studies. PLoS One 2015;10:e0131290, doi:http://dx.doi.org/10.1371/journal.pone.0131290.

[335] Long J-A, Bernhard J-C, Bigot P, Lanchon G, Paparel P, Rioux-Leclercq N, et al. Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting. World J Urol 2017;35:649–56, doi:http://dx.doi.org/10.1007/s00345-016-1913-4.

[336] Benichou Y, Audenet F, Bensalah K, Roupret M, Paparel P, Lebacle C, et al. Partial nephrectomy in solitary kidneys: comparison between open surgery and robotic-assisted laparoscopy on perioperative and functional outcomes (UroCCR-54 study). World J Urol 2023;41:315–24, doi:http://dx.doi.org/10.1007/s00345-022-04026-y.

[337] Badani KK, Kothari PD, Okhawere KE, Eun D, Hemal A, Abaza R, et al. Selective clamping during robot-assisted partial nephrectomy in patients with a solitary kidney: is it safe and does it help? BJU Int 2020;125:893–7, doi:http://dx.doi.org/10.1111/bju.15043.

[338] Attawettaytan W, Yasuda Y, Zhang JH, Rathi N, Munoz-Lopez C, Kazama A, et al. Functional recovery after partial nephrectomy in a solitary kidney. Urol Oncol 2024;42:32.e17–27, doi:http://dx.doi.org/10.1016/j.urolonc.2023.12.004.

[339] Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, et al. Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol 2010;58:331–6, doi:http://dx.doi.org/10.1016/j.eurouro.2010.05.048.

[340] Anceschi U, Brassetti A, Bertolo R, Tuderti G, Ferriero MC, Mastroianni R, et al. On-clamp versus purely off-clamp robot-assisted partial nephrectomy in solitary kidneys: comparison of perioperative outcomes and chronic kidney disease progression at two high-volume centers. Minerva Urol Nephrol 2021;73:739–45, doi:http://dx.doi.org/10.23736/S2724-6051.20.03795-9.

[341] Brassetti A, Cacciamani GE, Mari A, Garisto JD, Bertolo R, Sundaram CP, et al. On-clamp vs. off-clamp robot-assisted partial nephrectomy for cT2 renal tumors: retrospective propensity-score-matched multicenter outcome analysis. Cancers 2022;14:4431, doi:http://dx.doi.org/10.3390/cancers14184431.

[342] Tillou X, Doerfler A, Szabla N, Verhoest G, Defortescu G, Bessedé T, et al. [Renal cell carcinoma of the kidney transplant: the French guidelines from CTAFU]. Prog Urol 2021;31:24–30, doi:http://dx.doi.org/10.1016/j.purol.2020.04.029.

[343] Griffith JJ, Akin MA, Waingankar N, Lerner SM, Delaney V, Ames SA, et al. Solid renal masses in transplanted allograft kidneys: a closer look at the epidemiology and management. Am J Transplant 2017;17:2775–81, doi:http://dx.doi.org/10.1111/ajt.14366.

[344] Minkovich M, Wong RBK, Fumare O, Li Y, Kim SJ, Lee JY. Renal cell carcinoma in kidney transplant recipients: incidence, trends, clinical management & outcomes. World J Urol 2023;41:2389–95, doi:http://dx.doi.org/10.1007/s00345-023-04495-9.

[345] Gigante M, Neuzillet Y, Patard J-J, Tillou X, Thuret R, Branchereau J, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int 2012;110:E570–3, doi:http://dx.doi.org/10.1111/j.1464-410X.2012.11273.x.

[346] Goujon A, Verhoest G, Sallusto F, Branchereau J, Boutin J-M, Bessedé T, et al. [Renal cell carcinoma in candidates for renal transplantation and recipients of a kidney transplant: the French guidelines from CTAFU]. Prog Urol 2021;31:18–23, doi:http://dx.doi.org/10.1016/j.purol.2020.04.030.

[347] Hora M, Hes O, Reischig T, Urge T, Klecka J, Ferda J, et al. Tumours in end-stage kidney. Transplant Proc 2008;40:3354–8, doi:http://dx.doi.org/10.1016/j.transproceed.2008.08.135.

[348] Pan H-C, Sun C-Y, Wu I-W, Tsai T-L, Sun C-C, Lee C-C. Higher risk of malignant neoplasms in young adults with end-stage renal disease receiving haemodialysis: a nationwide population-based study. Nephrology (Carlton) 2019;24:1165–71, doi:http://dx.doi.org/10.1111/nep.13555.

[349] Tillou X, Doerfler A, Collon S, Kleincauss F, Patard J-J, Badet L, et al. De novo kidney graft tumors: results from a multicentric retrospective national study. Am J Transplant 2012;12:3308–15, doi:http://dx.doi.org/10.1111/j.1600-6143.2012.04248.x.

[350] Vaudreuil L, Bessedé T, Boissier R, Bouye S, Branchereau J, Caillet K, et al. De novo renal carcinoma arising in non-functional kidney graft: a national retrospective study. Int Urol Nephrol 2020;52:1235–41, doi:http://dx.doi.org/10.1007/s11255-020-02422-0.

[351] Swords DC, Al-Geizawi SM, Farney AC, Rogers J, Burkart JM, Assimos DG, et al. Treatment options for renal cell carcinoma in renal allografts: a case series from a single institution. Clin Transplant 2013;27:E199–205, doi:http://dx.doi.org/10.1111/ctr.12088.

[352] Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J, et al. Biopsy-confirmed de novo renal cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort. BJU Int 2012;109:195–9, doi:http://dx.doi.org/10.1111/j.1464-410X.2011.10315 doi:

[353] Viart L, Surga N, Collon S, Jaureguy M, Elalouf V, Tillou X. The high rate of de novo graft carcinomas in renal transplant recipients. Am J Nephrol 2013;37:91–6, doi:http://dx.doi.org/10.1159/000346624.

[354] Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K. Renal cell carcinoma and kidney transplantation: a narrative review. Transplantation 2022;106:e52–63, doi:http://dx.doi.org/10.1097/TP.0000000000003762.

[355] Laclergerie F, Delchier M-C, Covin B, Sallusto F, Soulie M, Gamé X, et al. Robot-assisted laparoscopic partial nephrectomy with renal artery clamping using an endovascular balloon catheter for an allograft kidney tumor: a new perspective to manage renal vascular control? Am J Transplant 2019;19:1239–40, doi:http://dx.doi.org/10.1111/ajt.15151.

[356] Tydén G, Wernersson A, Sandberg J, Berg U. Development of renal cell carcinoma in living donor kidney grafts. Transplantation 2000;70:1650–6, doi:http://dx.doi.org/10.1097/00007890-200012150-00018.

[357] Mindrup S, Rayhill S, Fallon B. Renal cell carcinoma in a transplanted kidney. J Urol 2001;165:1990, doi:http://dx.doi.org/10.1097/00005392-200106000-00039.

[358] Cornelis F, Buy X, André M, Oyen R, Bouffard-Vercelli J, Blandino A, et al. De novo renal tumors arising in kidney transplants: midterm outcome after percutaneous thermal ablation. Radiology 2011;260:900–7, doi:http://dx.doi.org/10.1148/radiol.11110122.

[359] Gul ZG, Griffith JJ, Welch C, Fischman A, Palese MA, Badani KK, et al. Focal ablative therapy for renal cell carcinoma in transplant allograft kidneys. Urology 2019;125:118–22, doi:http://dx.doi.org/10.1016/j.urology.2018.12.003.

[360] Favi E, Raison N, Ambrogi F, Delbue S, Clementi MC, Lamperti L, et al. Systematic review of ablative therapy for the treatment of renal allograft neoplasms. World J Clin Cases 2019;7:2487–504, doi:http://dx.doi.org/10.12998/wjcc.v7.i17.2487.

[361] Tsur I, Obermüller N, Jonas D, Blaheta R, Juengel E, Scheuermann E-H, et al. De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. BJU Int 2011;108:229–34, doi:http://dx.doi.org/10.1111/j.1464-410X.2010.09856.x.

[362] Butler AM, Olshan AF, Kshirsagar AV, Edwards JK, Nielsen ME, Wheeler SB, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 2015;65:763–72, doi:http://dx.doi.org/10.1053/j.ajkd.2014.12.013.

[363] Ball MW, An JY, Gomella PT, Gautam R, Ricketts CJ, Vocke CD, et al. Growth rates of genetically defined renal tumors: implications for active surveillance and intervention. J Clin Oncol 2020;38:1146–53, doi:http://dx.doi.org/10.1200/JCO.19.02263.

[364] Gomella PT, Linehan W, Ball MW. Precision surgery and kidney cancer: knowledge of genetic alterations influences surgical management. Genes 2021;12:261, doi:http://dx.doi.org/10.3390/genes12020261.

[365] Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007;177:2074–9, doi:http://dx.doi.org/10.1016/j.juro.2007.01.155 [discussion 2079–2080].

[366] Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. JCO 2013;31:181–6, doi:http://dx.doi.org/10.1200/JCO.2012.43.3383.

[367] Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs. sunitinib in patients with met-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol 2020;6:1247–55, doi:http://dx.doi.org/10.1001/jamaoncol.2020.2218.

[368] Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutafan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021;385:2036–46, doi:http://dx.doi.org/10.1056/NEJMoa2103425.

[369] Nouhau F-X, Bernhard J-C, Bigot P, Khene Z-E, Audenet F, Lang H, et al. Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study). World J Urol 2018;36:1643–9, doi:http://dx.doi.org/10.1007/s00345-018-2307-6.

[370] Boissier R, Ouzaid I, Nouhau FX, Khene Z, Dariane C, Chkir S, et al. Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification. Int Urol Nephrol 2019;51:951–8, doi:http://dx.doi.org/10.1007/s11255-019-02085-6.
[371] Gerst S, Hann LE, Li D, Gonen M, Tickoo S, Sohn MJ, et al. Evaluation of renal masses with contrast-enhanced ultrasound: initial experience. AJR Am J Roentgenol 2011;197:897-906, doi:http://dx.doi.org/10.2214/AJR.10.6330.

[372] Defortescu G, Cornu J-N, Béjar S, Giwerc A, Gobet F, Werquin M, et al. Diagnostic performance of contrast-enhanced ultrasonography and magnetic resonance imaging for the assessment of complex renal cysts: a prospective study. Int J Urol 2017;24:184-9, doi:http://dx.doi.org/10.1111/iju.13289.

[373] Silverman SG, Pedrosa I, Ellis JH, Hindman NM, Schiede N, Smith AD, et al. Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment. Radiology 2019;292:475-88, doi:http://dx.doi.org/10.1148/radiol.2019182646.

[374] Bosniak MA. The Bosniak renal cyst classification: 25 years later. Radiology 2012;262:781-5, doi:http://dx.doi.org/10.1148/radiol.11111595.

[375] Warren KS, McFarlane J. The Bosniak classification of renal cystic masses. BJU Int 2005;95:939-42, doi:http://dx.doi.org/10.1111/j.1464-410X.2005.05442.x.

[376] Ramachandran A. Differentiating benign from malignant cystic renal masses using CT texture-based machine learning algorithms. Radiol Imaging Cancer 2024;6: e249007, doi:http://dx.doi.org/10.1148/rycan.249007.

[377] Schoots IG, Zaccai K, Hunink MG, Verhagen PCMS. Bosniak classification for complex renal cysts reevaluated: a systematic review. J Urol 2017;198:12-21, doi: http://dx.doi.org/10.1016/j.juro.2016.09.160.

[378] Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660-73, doi:http://dx.doi.org/10.1016/j.euro.2015.07.072.

[379] Westerman ME, Cheville V, Lohse CM, Sharma V, Boorjian SA, Leibovich BC, et al. Long-term outcomes of patients with low grade cystic renal epithelial neoplasms. Urology 2019;133:145-50, doi:http://dx.doi.org/10.1016/j.urology.2019.07.017.

[380] Pradere B, Peyronnet B, Delporte G, Manach Q, Khene Z-E, Moulin M, et al. Intraoperative cyst rupture during partial nephrectomy for cystic renal masses-does it increase the risk of recurrence? J Urol 2018;200:1200-6, doi:http://dx.doi.org/10.1016/j.juro.2018.06.025.

[381] Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs - part A: renal, penile, and testicular tumours. Eur Urol 2016;70:93-105, doi:http://dx.doi.org/10.1016/j.euro.2016.02.029.

[382] Adamy A, Lowrance WT, Yee DS, Chong KT, Bernstein M, Tickoo SK, et al. Renal oncocytosis: management and clinical outcomes. J Urol 2011;185:795-801, doi: http://dx.doi.org/10.1016/j.juro.2010.10.068.

[383] Hes O, Petersson F, Kuroda N, Hora M, Michal M. Renal hybrid oncocytic/chromophobe tumors - a review. Histol Histopathol 2013;28:1257-64, doi:http://dx.doi.org/10.14670/HHV-28.1257.

[384] Baboudjian M, Moser D, Yanagisawa T, Gondran-Tellier B, Compérat EM, Ambrosetti D, et al. Benefit and harm of active surveillance for biopsy-proven renal oncocytoma: a systematic review and pooled analysis. Eur Urol Open Sci 2022;41:8-15, doi: http://dx.doi.org/10.1016/j.euros.2022.04.009.

[385] Deledalle F-X, Ambrosetti D, Durand M, Michel F, Baboudjian M, Gondran-Tellier B, et al. Active surveillance for biopsy proven renal oncocytomas: outcomes and feasibility. Urology 2021;156:185-90, doi:http://dx.doi.org/10.1016/j. urology.2021.05.034 [S0090-4295(21)00453-2].

[386] Patel HD, Druskin SC, Rowe SP, Pierozario PM, Gorin MA, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 2017;119:661-6, doi:http://dx.doi.org/10.1111/bju.13763.

[387] Neuzillet Y, Lechevalier E, Andre M, Daniel L, Nahon O, Coulange C. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology 2005;66:1181-5, doi:http://dx.doi.org/10.1016/j.urology.2005.06.001.

[388] Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MAS. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J Urol 2011;186:1218-22, doi:http://dx.doi.org/10.1016/j. juro.2011.05.080.

[389] Kurup AN, Thompson RH, Leibovich BC, Harmsen WS, Sebo TJ, Callstrom MR, et al. Renal oncocytoma growth rates before intervention. BJU Int 2012;110:1444-8, doi: http://dx.doi.org/10.1111/j.1464-410X.2012.011136.x.

[390] Richard PO, Jewett MAS, Bhatt JR, Evans AJ, Timilsina N, Finelli A. Active surveillance for renal neoplasms with bacteriuria features is safe. J Urol 2016;195:581-6, doi:http://dx.doi.org/10.1016/j.juro.2015.09.067.

[391] Liu S, Lee S, Rashid P, Bangash H, Hamid A, Lau J, et al. Active surveillance is suitable for intermediate term follow-up of renal oncocytoma diagnosed by percutaneous core biopsy. BJU Int 2016;118(Suppl. 3):30-4, doi:http://dx.doi.org/10.1111/bju.13538.

[392] Alderman MA, Daignault S, Wolf JS, Palapattu GS, Weizer AZ, Hafez KS, et al. Categorizing renal oncocytic neoplasms on core needle biopsy: a morphologic and immunophenotypic study of 144 cases with clinical follow-up. Hum Pathol 2016;55:1-10, doi:http://dx.doi.org/10.1016/j.humpath.2016.03.017.

[393] Neves JB, Varley R, Agnesi S, Withington J, Rodrigues FB, Warren H, et al. Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. BJU Int 2021;128:722-7, doi:http://dx.doi.org/10.1111/bju.15499.

[394] Deledalle F-X, Ambrosetti D, Durand M, Michel F, Baboudjian M, Gondran-Tellier B, et al. Active surveillance for biopsy proven renal oncocytomas: outcomes and feasibility. Urology 2021;156:185-90, doi:http://dx.doi.org/10.1016/j. urology.05.034 [S0090-4295(21)00453-2].

[395] Meagher MF, Lane BR, Capitano U, Mehrazin R, Bradshaw AJW, Noyes S, et al. Comparison of renal functional outcomes of active surveillance and partial nephrectomy in the management of oncocytoma. World J Urol 2021;39:1195-201, doi:http://dx.doi.org/10.1007/s00345-020-03299-5.

[396] Miller BL, Mankowski Gettle L, Van Roo JR, Ziemlewicz TJ, Best SL, Wells SA, et al. Comparative analysis of surgery, thermal ablation, and active surveillance for renal oncocytic neoplasms. Urology 2018;112:92-7, doi:http://dx.doi.org/10.1016/j. urology.2017.09.016.

[397] Tamboli P, Ro JY, Amin MB, Ligato S, Ayala AG. Benign tumors and tumor-like lesions of the adult kidney. Part II: benign mesenchymal and mixed neoplasms, and tumor-like lesions. Adv Anat Pathol 2000;7:47-66, doi:http://dx.doi.org/10.1097/ 00125480-200007010-00007.

[398] Flum AS, Hamoui N, Said MA, Yang XJ, Casalino DD, McGuire BB, et al. Update on the diagnosis and management of renal angiomyolipoma. J Urol 2016;195:834-46, doi: http://dx.doi.org/10.1016/j.juro.2015.07.126.

[399] Simpfendorfer C, Herts BR, Motta-Ramirez GA, Lockwood DS, Zhou M, Leiber M, et al. Angiomyolipoma with minimal fat on MDCT: can counts of negative- attenuation pixels aid diagnosis? AJR Am J Roentgenol 2009;192:438-43, doi: http://dx.doi.org/10.2214/AJR.08.1180.

[400] Sivalingam S, Nakada SY. Contemporary minimally invasive treatment options for renal angiomyolipomas. Curr Urol Rep 2013;14:147-53, doi:http://dx.doi.org/ 10.1007/s11934-013-0311-3.

[401] Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries P J, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50-66, doi:http://dx.doi. org/10.1016/j.pediatneurol.2021.07.011.

[402] Zhang JQ, Fielding JR, Zou KH. Etiology of spontaneous perirenal hemorrhage: a meta-analysis. J Urol 2002;167:1593-6, doi:http://dx.doi.org/10.1097/00005392- 200204000-00006.

[403] Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, et al. Management of sporadic renal angiomyolipomas: a systematic review of available evidence to guide recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. Eur Urol Oncol 2020;3:57-72, doi:http://dx.doi.org/10.1016/j.euo.2019.04.005.

[404] Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-24, doi: http://dx.doi.org/10.1016/j.euro.2015.01.005.

[405] Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. J Urol 1986;135:1121-4, doi:http://dx.doi.org/10.1016/s0022- 5347(17)46013-7.

[406] Ouzaid I, Autorino R, Fatica R, Herts BR, McLennan G, Remer EM, et al. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. BJU Int 2014;114:412-7, doi:http://dx.doi.org/10.1111/bju.12604.

[407] Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, et al. Natural history of renal angiomyolipoma (AML): most patients with large AMLs > 4 cm can be offered active surveillance as an initial management strategy. Eur Urol 2016;70:85-90, doi:http://dx.doi.org/10.1016/j.euro.2016.01.048.

[408] Grassano Y, Rollin P, Hermieu N, Schoentgen N, Xylinas E, Hermieu J-F, et al. [Results of active surveillance for sporadic renal angiomyolipomas greater than 4 cm: a pledge for active surveillance]. Prog Urol 2021;31:99-104, doi:http://dx.doi.org/ 10.1016/j.purol.2020.08.004.

[409] Nese N, Martignoni G, Fletcher CD, Gupta R, Pan C-C, Kim H, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011;35:161-76, doi:http://dx.doi.org/10.1097/ PAS.0b013e318206f2a9.

[410] Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-56, doi:http://dx.doi.org/10.1056/NEJMra055323.

[411] Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, von Kries R, Heinrich B, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis 2018;13:117, doi:http://dx.doi.org/10.1186/s13023-018-0870-y.

[412] Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiolymphomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-24, doi:http://dx.doi.org/ 10.1016/S0140-6736(12)61767-X.

[413] Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Renal manifestations of tuberous sclerosis complex: key findings from the final analysis of the TOSCA study focussing mainly on renal angiomyolipomas. Front Neurol 2020;11:972, doi:http://dx.doi.org/10.3389/neur.2020.00972.

[414] Samama C-M, Albaladejo P, Lavers S, Marret E. [Prevention of venous thromboembolism in surgery and obstetrics]. Ann Fr Anesth Reanim 2005;24:853-61, doi:http://dx.doi.org/10.1016/j.annfar.2005.06.011.

[415] Tikkinen KAO, Craigie S, Agarwal A, Violette PD, Novara G, Cartwright R, et al. Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis. Eur Urol 2018;73:242-51, doi:http://dx.doi.org/10.1016/j.euro.2017.03.008.

[416] Azawi NH, Tolouee S, Dabestani S. Incidence and associated risk factors of venous thromboembolism after open and laparoscopic partial nephrectomy in patients administered short-period thromboprophylaxis: a Danish nationwide population-based cohort study. Scand J Urol 2023;57:81-5, doi:http://dx.doi.org/10.1080/ 21681805.2023.2171112.

[417] Ayoub E, Kutchukian S, Bigot P, Dinh A, Gondran-Tellier B, Robin H, et al. Asymptomatic bacteriuria prior to partial and radical nephrectomy: to screen or not to screen? Results from the national and multicenter TOCUS database. World J Urol 2024;42:179, doi:http://dx.doi.org/10.1007/s00345-024-04853-1.

[418] Chen Y-C, Chang Y-J, Tsou Y-C, Chen M-C, Pai Y-C. Effectiveness of nurse case management compared with usual care in cancer patients at a single medical center
in Taiwan: a quasi-experimental study. BMC Health Serv Res 2013;13:202, doi: http://dx.doi.org/10.1186/1472-6963-13-202.

[419] Chen S, He Z, Yao S, Xiong K, Shi J, Wang G, et al. Enhanced recovery after surgery protocol optimizes results and cost of laparoscopic radical nephrectomy. Front Oncol 2022;12:840363, doi:http://dx.doi.org/10.3389/fonc.2022.840363.

[420] Ingels A, Duc S, Bensalah K, Bigot P, Paparel P, Beauval J-B, et al. Postoperative outcomes of elderly patients undergoing partial nephrectomy. Sci Rep 2021;11:17201, doi:http://dx.doi.org/10.1038/s41598-021-96676-y.

[421] Dabestani S, Marconi L, Kuusk T, Bex A. Follow-up after curative treatment of localised renal cell carcinoma. World J Urol 2018;36:1953–9, doi:http://dx.doi.org/ 10.1007/s00345-018-2338-z.

[422] Beisland C, Guobrandsdottir G, Reiserer LAR, Bostad L, Hjelle KM. A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World J Urol 2016;34:1087–99, doi:http://dx.doi.org/10.1007/s00345-016-1796-4.

[423] Merrill SB, Sohl BS, Hamirani A, Lehman EB, Lehman KK, Kaag MG, et al. Capturing renal cell carcinoma recurrences when asymptomatic improves patient survival. Clin Genitourin Cancer 2019;17:132–8, doi:http://dx.doi.org/10.1016/j. clgc.2018.11.009.

[424] Bigot P, Bernhard J-C, Khene Z-E, Dariane C, Lebdai S, Doumerc N, et al. Nephrectomy for kidney tumour increases the risk of de novo arterial hypertension. BJU Int 2023;132:575–80, doi:http://dx.doi.org/10.111/j.bju.16124.

[425] Leppert JT, Lamberts RW, Thomas I-C, Chung BI, Sonn GA, Skinner EC, et al. Incident CKD after radical or partial nephrectomy. J Am Soc Nephrol 2018;29:207–16, doi: http://dx.doi.org/10.1681/ASN.2017020136.

[426] Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis. Eur Urol Focus 2019;5:857–66, doi:http://dx. doi.org/10.1016/j.euf.2018.02.010.

[427] Jamil ML, Keeley J, Sood A, Dalela D, Arora S, Peabody JO, et al. Long-term risk of recurrence in surgically treated renal cell carcinoma: a post hoc analysis of the Eastern Cooperative Oncology Group – American College of Radiology Imaging Network E2805 trial cohort. Eur Urol 2020;77:277–81, doi:http://dx.doi.org/ 10.1016/j.eurouro.2019.10.028.

[428] Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006;175:859–63, doi:http:// dx.doi.org/10.1016/S0022-5347(05)00526-4.

[429] Hu X, Liao D-W, Yang Z-Q, Yang W-X, Xiong S-C, Li X. Sarcopenia predicts prognosis of patients with renal cell carcinoma: a systematic review and meta-analysis. Int Braz J Urol 2020;46:705–15, doi:http://dx.doi.org/10.1590/S1677-5538. IBJU.2019.0636.

[430] Kim HL, Han K-R, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol 2004;171:1810– 3, doi:http://dx.doi.org/10.1097/01.ju.0000121440.82581.d3.

[431] Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. BMC Urol 2020;20:90, doi:http://dx.doi.org/10.1186/s12894-020- 00665-8.

[432] Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, et al. Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation. J Urol Focus 2022;8:182–90, doi:http://dx.doi.org/10.1016/j.euf.2021.02.009.

[433] Khor L-Y, Dhakal HP, Jia X, Reynolds JP, McKenney JK, Rini BI, et al. Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution. Am J Surg Pathol 2016;40:1224–31, doi:http://dx.doi.org/10.1097/PAS.0b013e182990fbf.

[434] Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37:1490–504, doi:http://dx.doi.org/10.1097/PAS.0b013e182990fbf.

[435] Bailey GC, Boorjian SA, Zieglermann MJ, Westerman ME, Lohse CM, Leibovich BC, et al. Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma. BJU Int 2017;119:585–90, doi:http://dx.doi. org/10.1111/bju.13669.

[436] Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen H-C, et al. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol 2015;33:427.e17–23, doi:http://dx.doi.org/10.1016/j.urolonc.2015.04.011.

[437] Kim T, Zargar-Shoshartki K, Dhillon J, Lin H-Y, Yue B, Fishman M, et al. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer 2015;13:225–30, doi:http://dx.doi.org/ 10.1016/j.clgc.2014.12.001.

[438] Petitprez F, Ayadi M, de Reyniès A, Fridman WH, Sautès-Fridman C, Job S. Review of prognostic expression markers for clear cell renal cell carcinoma. Front Oncol 2021;11:643065, doi:http://dx.doi.org/10.3389/fonc.2021.643065.

[439] Usher-Smith JA, Li L, Roberts L, Harrison H, Rossi SH, Sharp SJ, et al. Risk models for recurrence and survival after kidney cancer: a systematic review. BJU Int 2022;130:562–79, doi:http://dx.doi.org/10.1111/bju.15673.

[440] Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, et al. Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation. J Clin Oncol 2019;37:2062–71, doi:http://dx.doi. org/10.1200/JCO.19.00107.

[441] Khene Z-E, Larcher A, Bernhard J-C, Doumerc N, Ouzaid I, Capitanio U, et al. External validation of the ASSURE model for predicting oncological outcomes after resection of high-risk renal cell carcinoma (RESCUE study: UroCCR 88). Eur Urol Open Sci 2021;33:89–93, doi:http://dx.doi.org/10.1016/j.euros.2021.09.004.

[442] Kim JK, Lee S, Hong SK, Kwak C, Jeong CW, Kang SH, et al. Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database. Sci Rep 2023;13:5778, doi:http://dx.doi. org/10.1038/s41598-023-30826-2.

[443] Khene Z-E, Bigot P, Doumerc N, Ouzaid I, Boissier R, Nouhaud F-X, et al. Application of machine learning models to predict recurrence after surgical resection of nonmetastatic renal cell carcinoma. Eur Urol Oncol 2023;6:323–30, doi:http://dx. doi.org/10.1016/j.euo.2022.07.007.

[444] Margue G, Ferrer L, Etchepare G, Bigot P, Bensalah K, Mejean A, et al. UroPredict: machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120). Npj Precis Onc 2024;8:45, doi:http://dx.doi.org/ 10.1038/s41698-024-00532-x.

[445] Margue G, Ferrer L, Etchepare G, Bigot P, Bensalah K, Mejean A, et al. UroPredict: Machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120). NJP Precis Onc 2024;8:45, doi:http://dx.doi.org/ 10.1038/s41698-024-00532-x.

[446] Cindolo L, Chiodini P, Gallo C, Ficarra V, Schips L, Tostain J, et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2008;113:65–71, doi: http://dx.doi.org/10.1002/cncr.23517.

[447] Han K-R, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003;170:2221– 4, doi:http://dx.doi.org/10.1097/01.ju.0000096049.64863.a1.

[448] Patard J-J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22:3316– 22, doi:http://dx.doi.org/10.1200/JCO. 2004.09.104.

[449] Tolleson MK, Takahashi N, Leibovich BC. Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma. Curr Urol Rep 2007;8:38–43.

[450] Gires B, Khene Z-E, Bigot P, Alimi Q, Peyronnet B, Verhoest G, et al. Impact of routine imaging in the diagnosis of recurrence for patients with localized and locally advanced renal tumor treated with nephrectomy. J Urol 2019;37:2727–36, doi:http://dx.doi.org/10.1007/s00345-019-02724-8.

[451] Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007;99:296–300.

[452] Canvasser NE, Stouder K, Lay AH, Gahan JC, Lotan Y, Margulis V, et al. The usefulness of chest X-rays for T1a renal cell carcinoma surveillance. J Urol 2016;196:321–6, doi: http://dx.doi.org/10.1016/j.juro.2016.02.068.

[453] Casalino DD, Remer E, Bishoff JT, Coursey CA, Dighe M, Harvin HJ, et al. ACR appropriateness criteria post-treatment follow-up of renal cell carcinoma. J Am Coll Radiol 2014;11:443–9, doi:http://dx.doi.org/10.1016/j.jacr.2014.01.023.

[454] Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur Urol 2018;74:611–20, doi:http://dx.doi.org/ 10.1016/j.eurouro.2018.05.002.

[455] Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246–54, doi:http://dx.doi.org/10.1056/NEJMoa1611406.

[456] Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol 2021;79:334–8, doi:http://dx.doi.org/10.1016/j. eurouro.2020.12.029.

[457] Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008–16, doi:http://dx.doi.org/10.1016/S0140-6736(16)00559-6.

[458] Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375:2246–54, doi:http://dx.doi.org/10.1056/NEJMoa1611406.

[459] Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29:2371–8, doi:http://dx.doi.org/ 10.1093/annonc/mdy454.

[460] Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, et al. Everolimus exposure as a predictor of toxicity in renal cell cancer patients in the adjuvant setting: results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249). Kidney Cancer 2019;3:111–8, doi:http://dx.doi.org/10.3233/ KCA-180049.

[461] Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, et al. Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial. J Clin Oncol 2020;38:4064–75, doi: http://dx.doi.org/10.1200/JCO.20.01800.

[462] Choueiri TK, Powles T. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma, reply. N Engl J Med 2021;385:1920, doi:http://dx.doi.org/10.1056/ NEJMc2115204.

[463] Choueiri TK, Tomczak P, Park SH. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). Lancet Oncol 2022;23:1133–44.

[464] Choueiri TK, Tomczak P, Park SH, Venugopal B, Symeonides S, Hajek J, et al. Patient- reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma. Oncologist 2024;29:142–50, doi:http://dx.doi.org/10.1093/ oncolo/oyad231.
[465] Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289-300, doi:http://dx.doi.org/10.1056/NEJMoa2035716.

[466] Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370-85, doi:http://dx.doi.org/10.1016/S1470-2045(19)30413-9.

[467] Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:1563-73, doi:http://dx.doi.org/10.1016/S1470-2045(20)30436-8.

[468] Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829-41, doi:http://dx.doi.org/10.1056/NEJMoa2026982.

[469] Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 2023;401:821-32, doi:http://dx.doi.org/10.1016/S0140-6736(22)02574-0.

[470] Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, et al. Adjuvant atezolizumab versus placebo for patients with metastatic renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2022;400:1103-16, doi:http://dx.doi.org/10.1016/S0140-6736(22)01658-0.

[471] Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9, doi:http://dx.doi.org/10.1200/JCO.2008.21.4809.

[472] Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14:141-8, doi:http://dx.doi.org/10.1016/S1470-2045(12)70559-4.

[473] Ko JJ, Choueiri TK, Rini BI, Lee J-L, Kroeger N, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 2014;110:1917-22, doi:http://dx.doi.org/10.1038/bjc.2014.25.

[474] Kroeger N, Xie W, Lee J-L, Bjarnason GA, Knox JJ, Mackenzie MJ, et al. Metastatic non-clear renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119:2999-3006, doi:http://dx.doi.org/10.1002/cncr.28151.

[475] Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6, doi:http://dx.doi.org/10.1097/01.ju.000011061.61545.ae.

[476] Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379:417-27, doi:http://dx.doi.org/10.1056/NEJMoa1803675.

[477] Méjean A, Ravaud A, Thezenas S, Chevreau C, Bensalah K, Geoffrois L, et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80:417-24, doi:http://dx.doi.org/10.1016/j.euro.2021.06.009.

[478] Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of Immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5:164-70, doi:http://dx.doi.org/10.1001/jamaoncol.2018.5543.

[479] Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829-41, doi:http://dx.doi.org/10.1056/NEJMoa2026982.

[480] Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. N Engl J Med 2019;380:1116-27, doi:http://dx.doi.org/10.1056/NEJMoa1816714.

[481] Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103-15, doi:http://dx.doi.org/10.1056/NEJMoa1816047.

[482] Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384:1289-300, doi:http://dx.doi.org/10.1056/NEJMoa2035716.

[483] Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023;24:228-38, doi:http://dx.doi.org/10.1016/S1470-2045(23)00049-9.

[484] Mori K, Quhal F, Yanagisawa T, Katayama S, Pradere B, Laukhtina E, et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. Int Immunopharmacol 2022;108:108720, doi: http://dx.doi.org/10.1016/j.intimp.2022.108720.

[485] Singla N, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D, Sagalowsky AI, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol 2020;38:604.e9-604.e17, doi:http://dx.doi.org/10.1016/j.urolonc.2020.02.029.

[486] Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51, doi:http://dx.doi.org/10.1016/j.euro.2022.10.004.

[487] Chen B, Li J, Huang Y, Tang B, Jiang J, Chen Z, et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis. Int J Surg 2023;109:982-94, doi:http://dx.doi.org/10.1097/JSS.00000000000000314.

[488] Ghatalia P, Handorf EA, Geynisman DM, Deng M, Zibelman MR, Abbosh P, et al. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: a real-world multi-institutional trial. J Urol 2022;208:71-9, doi:http://dx.doi.org/10.1097/JU.00000000000002495.

[489] Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P, et al. Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma: a new surgical challenge? Eur Urol 2020;77:761-3, doi:http://dx.doi.org/10.1016/j.euro.2019.12.018.

[490] Singla N, Elias R, Ghandour RA, Freifeld Y, Bowman IA, Rapoport L, et al. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. Urol Oncol 2019;37:924-31, doi:http://dx.doi.org/10.1016/j.urolonc.2019.08.012.

[491] Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, et al. Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals. Eur Urol Open Sci 2023;50:43-6, doi:http://dx.doi.org/10.1016/j.euros.2023.01.016.

[492] Yip W, Ghoreifi A, Gerald T, Lee R, Howard A, Asghar A, et al. Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy: a multicenter collaborative study. Eur Urol Oncol 2023;6:604-10, doi:http://dx.doi.org/10.1016/j.euo.2023.03.003.

[493] Pignot G. Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma. Eur Urol Oncol 2022;5:577-84.

[494] Larcher A, Fallara G, Rosiello G, Re C, Baiamonte G, Agnesi S, et al. Cytoreductive nephrectomy in metastatic patients with signs or symptoms: implications for renal cell carcinoma guidelines. Eur Urol 2020;78:321-6, doi:http://dx.doi.org/10.1016/j.euro.2020.05.014.

[495] Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang Y-H, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385:683-94, doi:http://dx.doi.org/10.1056/NEJMoa2106391.

[496] Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75:111-28, doi:http://dx.doi.org/10.1016/j.euro.2018.09.016.

[497] Fiala O, Buti S, Biamas A, Massari F, Pichler R, Maruzzo M, et al. Real-world impact of upfront cytoreductive nephrectomy in metastatic non-clear renal cell carcinoma treated with first-line immunotherapy combinations or tyrosine kinase inhibitors (a sub-analysis from the ARON-1 retrospective study). Target Oncol 2014;29:587-99, doi:http://dx.doi.org/10.1007/s11523-024-01065-w.

[498] Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B, et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2019;2:141-9, doi:http://dx.doi.org/10.1016/j.euo.2018.08.028.

[499] Dabestani S, Marconi L, Hofmann F, Stewart F, Lam TBL, Canfield SE, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 2014;15:e549-61, doi:http://dx.doi.org/10.1016/S1470-2045(14)70235-9.

[500] Zaid HB, Parker WP, Safdar NS, Gershman B, Erwin PJ, Murad MH, et al. Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. J Urol 2017;197:44-9, doi:http://dx.doi.org/10.1016/j.juro.2016.07.079.

[501] Mikhail M, Chua KJ, Khizir L, Tabakin A, Singer EA. Role of metastasectomy in the management of renal cell carcinoma. Front Surg 2022;9:943604, doi:http://dx.doi.org/10.3389/fsgs.2022.943604.

[502] Fares AF, Araujo DV, Calsavara V, Saito AO, Formiga MN, Dettino AA, et al. Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. Ecantermedicalscience 2019;13:967, doi:http://dx.doi.org/10.3332/ecaner.2019.967.

[503] Wu K, Liu Z, Shao Y, Li X. Nomogram predicting survival to assist decision-making of metastasectomy in patients with metastatic renal cell carcinoma. Front Oncol 2020;10:592243, doi:http://dx.doi.org/10.3389/fonc.2020.592243.

[504] Lyon TD, Thompson RH, Shah PH, Lohse CM, Boorjian SA, Costello BA, et al. Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era. J Urol 2020;203:275-82, doi:http://dx.doi.org/10.1097/JU.0000000000000488.

[505] Hsieh P-Y, Hung S-C, Li J-R, Wang S-S, Yang C-K, Chen C-S, et al. The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol 2021;39:422-30, doi:http://dx.doi.org/10.1016/j.urolonc.2021.02.026.

[506] Tayeh GA, Alkassis M, De La Taille A, Vordos D, Champy CM, Pelegrin T, et al. Surgical metastasectomy for metastatic renal cell carcinoma in the era of targeted and immune therapy: a narrative review. World J Urol 2024;42:51, doi:http://dx.doi.org/10.1007/s00345-023-04706-3.

[507] Stühler V, Herrmann L, Maas M, Walz S, Rausch S, Stenzl A, et al. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immunology-based combination therapies. World J Urol 2022;40:1175-83, doi:http://dx.doi.org/10.1007/s00345-022-03960-1.

[508] Dragomir A, Nazha S, Wood LA, Rendon RA, Finelli A, Hansen A, et al. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian
Kidney Cancer information system experience. Urol Oncol 2020;38:799.e1-799.e10, doi:http://dx.doi.org/10.1016/j.urolonc.2020.07.021.

[509] Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, et al. Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: analysis of the REMARCC registry. Clin Genitourin Cancer 2022;20:326-33, doi:http://dx.doi.org/10.1016/j.clgc.2022.03.013.

[510] Lyon TD, Roussel E, Sharma V, Carames G, Lohse CM, Costello BA, et al. International multi-institutional characterization of the perioperative morbidity of metastasectomy for renal cell carcinoma. Eur Urol Oncol 2023;6:76-83, doi:http://dx.doi.org/10.1016/j.euo.2022.11.003.

[511] Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, et al. Stereotactic ablative radiation therapy (SABr) used to defer systemic treatment in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 2019;105:367-75, doi:http://dx.doi.org/10.1016/j.ijrobp.2019.07.023.

[512] Wang CJ, Christie A, Lin M-H, Jung M, Weix D, Huelsmann L, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 2017;98:91-100, doi:http://dx.doi.org/10.1016/j.ijrobp.2017.01.032.

[513] Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol 2019;2:515-23, doi:http://dx.doi.org/10.1016/j.euo.2019.05.007.

[514] Franzese C, Franceschini D, Di Brina L, D'Agostino GR, Navarria P, Comito T, et al. Role of stereotactic body radiation therapy for the management of oligometastatic renal cell carcinoma. J Urol 2019;201:70-5, doi:http://dx.doi.org/10.1016/j.juro.2018.08.049.

[515] Ingrosso G, Becherini C, Francolini G, Lancia A, Ali E, Caini S, et al. Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: a systematic review. Crit Rev Oncol Hematol 2021;159:103242, doi:http://dx.doi.org/10.1016/j.critrevonc.2021.103242.

[516] Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S, et al. Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy. World J Urol 2021;39:4183-90, doi: http://dx.doi.org/10.1007/s00345-021-03742-1.

[517] Meyer E, Pasquier D, Bernadou G, Calais G, Maroun P, Bossi A, et al. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the Getug group. Eur J Cancer 2018;98:38-47, doi:http://dx.doi.org/10.1016/j.ejca.2018.04.008.

[518] Hannan R, Christensen M, Christie A, Garant A, Pedrosa I, Robles L, et al. Stereotactic ablative radiation for systemic therapy naïve oligometastatic kidney cancer. Eur Urol Oncol 2022;5:695-703, doi:http://dx.doi.org/10.1016/j.euo.2022.06.008.

[519] Cheung P, Patel S, North SA, Sahal A, Chu W, Soliman H, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol 2021;80:693-700, doi:http://dx.doi.org/10.1016/j.eururo.2021.07.026.

[520] Masini C, Iotti C, De Giorgi U, Bellia RS, Buti S, Salaroli F, et al. Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study. Eur Urol 2022;81:274-82, doi:http://dx.doi.org/10.1016/j.eururo.2021.09.016.

[521] Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, et al. Stereotactic Radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma - the RAPPORT trial. Eur Urol 2022;81:364-72, doi:http://dx.doi.org/10.1016/j.eururo.2021.12.006.

[522] Luijoori A, Miller JA, Parsai S, Kotecha R, Ahluwalia MS, Mohammadi AM, et al. Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases. J Neurosurg 2019;132:188-96, doi: http://dx.doi.org/10.3171/2018.8.JNS182100.

[523] Fokas E, Henzel M, Hamm K, Surber G, Kleinert M, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery? Analysis of 88 patients. Strahlenther Onkol 2010;186:210-7, doi:http://dx.doi.org/10.1007/s00066-010-2055-z.

[524] Langrand-Escure J, Vallard A, Rivoirard R, Méry B, Guy J-B, Espenel S, et al. Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report. Anticancer Drugs 2016;27:427-32, doi:http://dx.doi.org/10.1097/CAD.0000000000000349.

[525] Klausner G, Troussier I, Biau J, Jacob J, Schernberg A, Canova C-H, et al. Stereotactic radiation therapy for renal cell carcinoma brain metastases in the tyrosine kinase inhibitors era: outcomes of 120 patients. Clin Genitourin Cancer 2019;17:191-200, doi:http://dx.doi.org/10.1016/j.clgc.2019.02.007.

[526] Peng J, Lalani A-K, Swaminath A. Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors in metastatic renal cell carcinoma. Can Urol Assoc J 2021;15:281-6, doi:http://dx.doi.org/10.5489/cuaj.6963.

[527] de Bâère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015;26:987-91, doi:http://dx.doi.org/10.1093/annonc/mdl037.

[528] Shu Yan Huo A, Lawson Morris D, King J, Glenn D. Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma. Ann Surg Oncol 2009;16:3169-75, doi:http://dx.doi.org/10.1245/s10434-009-0664-5.

[529] Soga N, Yamakado K, Gohara H, Takaki H, Hiraki T, Yamada T, et al. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int 2009;104:790-4, doi:http://dx.doi.org/10.1111/j.1464-410X.2009.08459.x.

[530] Hasegawa T, Yamakado K, Nakatsuka A, Uraki J, Yamanaka T, Fujimori M, et al. Unresectable adrenal metastases: clinical outcomes of radiofrequency ablation. Radiology 2015;277:584-93, doi:http://dx.doi.org/10.1148/radiol.2015142029.

[531] Gonnet A, Salabert L, Roubaud G, Catena V, Brouste V, Buy X, et al. Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer 2019;19:1182, doi: http://dx.doi.org/10.1186/s12885-019-6345-2.

[532] Welch BT, Callstrom MR, Morris JM, Kurup AN, Schmit GD, Weisbrod AJ, et al. Feasibility and oncologic control after percutaneous image guided ablation of metastatic renal cell carcinoma. J Urol 2014;192:357-63, doi:http://dx.doi.org/10.1016/j.juro.2014.03.006.

[533] Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277-90, doi:http://dx.doi.org/10.1056/NEJMoa1712126.

[534] Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5:e001079, doi:http://dx.doi.org/10.1136/esmoopen-2020-001079.

[535] Tannir N, Escudier B, McDermott D. Nivolumab plus ipilimumab (NIVO + IPI) vs. sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial. J Clin Oncol 2024 [S0923-7534(24)01516-3].

[536] Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21:1563-73, doi:http://dx.doi.org/10.1016/S1470-2045(20)30436-8.

[537] Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Urol 2023;84:449-54, doi:http://dx.doi.org/10.1016/j.eururo.2023.06.006.

[538] Bourlon MT, Escudier B, Burotto M. Nivolumab plus cabozantinib (N + C) vs. sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): results from 55-month follow-up of the CheckMate 9ER trial. Lancet Oncol 2022;23:888-98.

[539] Motzer R, Porta C, Masatoshi E. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: first preprespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol 2024;42:1222-8.

[540] Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13, doi:http://dx.doi.org/10.1056/NEJMoa1510665.

[541] Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27, doi:http://dx.doi.org/10.1016/S1470-2045(16)30107-3.

[542] Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 2023;402:185-95, doi:http://dx.doi.org/10.1016/S0140-6736(23)00922-4.

[543] Suárez C, Larkin JMG, Patel P, Valderrama BP, Rodriguez-Vida A, Glen H, et al. Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol 2023;41:2493-502, doi: http://dx.doi.org/10.1200/JCO.22.01414.

[544] Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, et al. Efficacy of savolitinib vs. sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol 2020;6:1247-55, doi:http://dx.doi.org/10.1001/jamaoncol.2020.2218.

[545] Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 2021;397:695-703, doi:http://dx.doi.org/10.1016/S0140-6736(21)00152-5.

[546] Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 2016;17:378-88, doi:http://dx.doi.org/10.1016/S1470-2045(15)00515-X.

[547] Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, et al. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: results of the multicentre, open-label, single-arm, phase II AXIPAP trial. Eur J Cancer 2020;129:107-16, doi:http://dx.doi.org/10.1016/j.ejca.2020.02.001.

[548] Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2016;69:866-74, doi:http://dx.doi.org/10.1016/j.eururo.2015.10.049.

[549] Escudier B, Molinie V, Bracarda S, Maroto P, Szczylik C, Nathan P, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2016;69:226-35, doi:http://dx.doi.org/10.1016/j.ejca.2016.08.004.

[550] Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. J Ann Oncol 2015;26:1123-8, doi:http://dx.doi.org/10.1093/annonc/mdl149.

[551] McDermott DF, Lee J-L, Ziobro M, Suarez C, Langiewicz P, Matveev VB, et al. Study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-
clear cell renal cell carcinoma. J Clin Oncol 2021;39:1029–39, doi:http://dx.doi.org/10.1200/JCO.20.02365.

[552] Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2023;24:881–91, doi:http://dx.doi.org/10.1016/S1470-2045(23)00276-0.

[553] Lee C-H, Voss MH, Carlo MI, Chen Y-B, Zucker M, Knezevic A, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 2022;40:2333–41, doi:http://dx.doi.org/10.1200/JCO.21.01944.

[554] Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Études des Tumeurs Uro-Génitales) study. J Urol 2007;177:1698–702, doi:http://dx.doi.org/10.1016/j.juro.2007.01.063.

[555] Sheng X, Cao D, Yuan J, Zhou F, Wei Q, Xie X, et al. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: a prospective, multicentre, single-arm, phase 2 study. Eur J Cancer 2018;100:1–7, doi:http://dx.doi.org/10.1016/j.ejca.2018.04.007.

[556] Procopio G, Sepe P, Claps M, Buti S, Solecchia M, Giannatempo P, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 study). JAMA Oncol 2022;8:910, doi:http://dx.doi.org/10.1001/jamaoncol.2022.0238.

[557] Thibault C, Fléchon A, Albiges L, Joly C, Barthelemy P, Gross-Goupil M, et al. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: results of a prospective phase II trial (BEVABEL-GETUG/AFU24). Eur J Cancer 2023;186:83–90, doi:http://dx.doi.org/10.1016/j.ejca.2023.03.018.